Инфекционный эндокардит и инфекция внутрисердечных устройств. Клинические рекомендации 2025

Кобалава Ж. Д.; Демин А. А.; Титов Д. А.; Козлов Р. С.; Артюхина Е. А.; Бойцов С. А.; Голухова Е. З.; Гордеев М. Л.; Гудымович В. Г.; Демченко Е. А.; Дробышева В. П.; Домонова Э. А.; Драпкина О. М.; Загородникова К. А.; Иртюга О. Б.; Калашников С. В.; Кахкцян П. В.; Киров М. Ю.; Кузьков В. В.; Котова Е. О.; Лебединский К. М.; Медведев А. П.; Муратов Р. М.; Николаевский Е. Н.; Писарюк А. С.; Пономарева Е. Ю.; Попов Д. А.; Рачина С. А.; Проценко Д. Н.; Ревишвили А. Ш.; Резник И. И.; Рыжкова Д. В.; Сазонова Ю. В.; Сафарова А. Ф.; Скопин И. И.; Тазина С. Я.; Тюрин В. П.; Федосейкина М. И.; Чипигина Н. С.; Шадрина У. М.; Шляхто Е. В.; Шнейдер Ю. А.; Шостак Н. А.

Статья

Инфекционный эндокардит и инфекция внутрисердечных устройств. Клинические рекомендации 2025

Кобалава Ж. Д., Демин А. А., Титов Д. А., Козлов Р. С., Артюхина Е. А., Бойцов С. А., Голухова Е. З., Гордеев М. Л., Гудымович В. Г., Демченко Е. А., Дробышева В. П., Домонова Э. А., Драпкина О. М., Загородникова К. А., Иртюга О. Б., Калашников С. В., Кахкцян П. В., Киров М. Ю., Кузьков В. В., Котова Е. О., Лебединский К. М., Медведев А. П., Муратов Р. М., Николаевский Е. Н., Писарюк А. С., Пономарева Е. Ю., Попов Д. А., Рачина С. А., Проценко Д. Н., Ревишвили А. Ш., Резник И. И., Рыжкова Д. В., Сазонова Ю. В., Сафарова А. Ф., Скопин И. И., Тазина С. Я., Тюрин В. П., Федосейкина М. И., Чипигина Н. С., Шадрина У. М., Шляхто Е. В., Шнейдер Ю. А., Шостак Н. А.

2026

https://doi.org/10.15829/1560-4071-2026-6853

Российское кардиологическое общество (РКО)При участии: Ассоциации сердечно-сосудистых хирургов России (АССХ), Российского научного медицинского общества терапевтов (РНМОТ), Всероссийского научно-практического общества эпидемиологов, микробиологов и паразитологов (ВНПОЭМП), Межрегиональной ассоциации по клинической микробиологии и антимикробной химиотерапии (МАКМАХ), Российского общества ядерной медицины (РОЯМ), Всероссийского научного общества специалистов по клинической электрофизиологии, аритмологии и кардиостимуляции (ВНОА)Одобрено на заседании Научно-практического совета Министерства здравоохранения Российской Федерации (заседание от 04.12.2025)

Цитирование

Список литературы

1. Habib G, Hoen B, Tornos P, et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer. Eur Heart J. 2009;30(19):2369-413. doi:10.1093/eurheartj/ehp285.

2. Habib G, Lancellotti P, Antunes MJ, et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J. 2015;36(44):3075-128. doi:10.1093/eurheartj/ehv319.

3. Демин А. А. Кардиология. Национальное руководство. (под ред. акад. Е. В. Шляхто). Гл. 19 "Инфекционный эндокардит". 3-е изд. М.: ГЭОТАР-Медиа, 2018. 816 с.

4. Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC Guidelines for the management of endocarditis. Eur Heart J. 2023;44(39):3948-4042. doi:10.1093/eurheartj/ehad193.

5. Андреева Н. С., Реброва О. Ю., Зорин Н. А. и др. Системы оценки достоверности научных доказательств и убедительности рекомендаций: сравнительная характеристика и перспективы унификации. Медицинские технологии. Оценка и выбор. 2012;(4):10-24.

6. Иртюга О. Б., Чистякова В. И., Тенчурина А. О. и др. Частота выявления и клиническая значимость латентного инфекционного эндокардита у пациентов с аортальным стенозом. Российский кардиологический журнал. 2019;(11):10-5. doi:10.15829/1560-4071-2019-11-10-15.

7. Habib G, Erba PA, Iung B, et al. Clinical presentation, aetiology and outcome of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry: a prospective cohort study. Eur Heart J. 2019;40(39):3222-32. doi:10.1093/eurheartj/ehz620.

8. Данилов А. И., Козлов Р. С., Козлов С. Н., Евсеев А. В. Практика проведения микробиологической диагностики инфекционного эндокардита в Российской Федерации. Вестник Смоленской государственной медицинской академии. 2019;1(18):90-4. EDN: XZDMHG.

9. Тюрин В. П. Инфекционные эндокардиты. М.: ГЭОТАР-Медиа, 2012. 243 c.

10. Yew HS, Murdoch DR. Global trends in infective endocarditis epidemiology. Curr Infect Dis Rep. 2012;14(4):367-72. doi:10.1007/s11908-012-0265-5.

11. Liesenborghs L, Meyers S, Vanassche T, Verhamme P. Coagulation: At the heart of infective endocarditis. J Thromb Haemost. 2020;18(5):995-1008. doi:10.1111/jth.14736.

12. Roth GA, Mensah GA, Johnson CO, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. J Am Coll Cardiol. 2020;76(25):2982-3021. doi:10.1016/j.jacc.2020.11.010.

13. Шевченко Ю. Л. Инфекционный эндокардит. Руководство по кардиологии в четырех томах. Том 4: Заболевания сердечно-сосудистой системы (II): под ред. акад. Е. И. Чазова. М.: Практика, 2014. 495 c.

14. Ambrosioni J, Hernandez-Meneses M, Téllez A, et al. The Changing Epidemiology of Infective Endocarditis in the Twenty-First Century. Curr Infect Dis Rep. 2017;19(5):21. doi:10.1007/s11908-017-0574-9.

15. Scully PR, Woldman S, Prendergast BD. Infective endocarditis: we could (and should) do better. Heart. 2021;107(2):96-8. doi:10.1136/heartjnl-2020-317671.

16. Моисеев В. С., Кобалава Ж. Д., Писарюк А. С. и др. Инфекционный эндокардит: клиническая характеристика и исходы (7-летний опыт лечения и наблюдения в многопрофильной городской больнице). Кардиология. 2018;58(12):66-75. doi:10.18087/cardio.2018.12.10192.

17. Balda J, Alpizar-Rivas R, Elarabi S, et al. Recent Trends in Infective Endocarditis Among Patients with and Without Injection Drug Use: An Eight-Year Single Center Study. Am J Med Sci. 2021;362(6):562-9. doi:10.1016/j.amjms.2021.07.009.

18. Talha KM, Dayer MJ, Thornhill MH, et al. Temporal Trends of Infective Endocarditis in North America From 2000 to 2017-A Systematic Review. Open Forum Infect Dis. 2021;8(11): ofab479. doi:10.1093/ofid/ofab479.

19. Пономарева Е. Ю., Ландфанг С. В. Анализ госпитальной летальности при инфекционном эндокардите. Фундаментальные исследования. 2015;1(6):1222-5. EDN: TWTPZT.

20. McDonald JR. Acute infective endocarditis. Infect Dis Clin North Am. 2009;23(3):643-64. doi:10.1016/j.idc.2009.04.013.

21. Kusumoto FM, Schoenfeld MH, Wilkoff BL, et al. 2017 HRS expert consensus statement on cardiovascular implantable electronic device lead management and extraction. Heart Rhythm. 2017;14(12): e503-e551. doi:10.1016/j.hrthm.2017.09.001.

22. Thuny F, Di Salvo G, Belliard O, et al. Risk of embolism and death in infective endocarditis: prognostic value of echocardiography: a prospective multicenter study. Circulation. 2005;112(1):69-75. doi:10.1161/CIRCULATIONAHA.104.493155.27.

23. Федорова Т. А., Тазина С. Я., Семененко Н. А. и др. Актуальные проблемы инфекционного эндокардита. Вестник Национального медико-хирургического Центра им. Н. И. Пирогова. 2014:125-7. EDN: WZCGFT.

24. Schwiebert R, Baig W, Wu J, Sandoe JAT. Diagnostic accuracy of splinter haemorrhages in patients referred for suspected infective endocarditis. Heart. 2022: heartjnl-2022-321052. doi:10.1136/heartjnl-2022-321052.

25. Grable C, Yusuf SW, Song J, et al. Characteristics of infective endocarditis in a cancer population. Open Heart. 2021;8(2): e001664. doi:10.1136/openhrt-2021-001664.

26. Pérez de Isla L, Zamorano J, Lennie V, et al. Negative blood culture infective endocarditis in the elderly: long-term follow-up. Gerontology. 2007;53(5):245-9. doi:10.1159/000101691.

27. Wong CY, Zhu W, Aurigemma GP, et al. Infective Endocarditis Among Persons Aged 18-64 Years Living with Human Immunodeficiency Virus, Hepatitis C Infection, or Opioid Use Disorder, United States, 2007-2017. Clin Infect Dis. 2021;72(10):1767-81. doi:10.1093/cid/ciaa372.

28. Li JS, Sexton DJ, Mick N, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis. 2000;30(4):633-8. doi:10.1086/313753.

29. Klug D, Lacroix D, Savoye C, et al. Systemic infection related to endocarditis on pacemaker leads: clinical presentation and management. Circulation. 1997;95(8):2098-107. doi:10.1161/01.cir.95.8.2098.

30. Habib G, Derumeaux G, Avierinos J-F, et al. Value and limitations of the duke criteria for the diagnosis of infective endocarditis. J Am Coll Cardiol. 1999;33:2023-9. doi:10.1016/S0735-1097(99)00116-3.141.

31. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease. J Thorac Cardiovasc Surg. 2014;148:e1-132. doi:10.1016/j.jtcvs.2014.05.014.

32. Sarrazin J-F, Philippon F, Tessier M, et al. Usefulness of Fluorine-18 Positron Emission Tomography/Computed Tomography for Identification of Cardiovascular Implantable Electronic Device Infections. J Am Coll Cardiol. 2012;59:1616-25. doi:10.1016/j.jacc.2011.11.059.

33. Scholtens AM, Swart LE, Verberne HJ, et al. Confounders in FDG-PET/CT Imaging of Suspected Prosthetic Valve Endocarditis. JACC Cardiovasc Imaging. 2016;9(12):1462-5. doi:10.1016/j.jcmg.2016.01.024.

34. Pizzi MN, Roque A, Cuéllar-Calabria H, et al. 18F-FDG-PET/CTA of Prosthetic Cardiac Valves and Valve-Tube Grafts: Infective Versus Inflammatory Patterns. JACC Cardiovasc Imaging. 2016;9(10):1224-7. doi:10.1016/j.jcmg.2016.05.013.

35. Dahl A, Fowler VG, Miro JM, Bruun NE. Sign of the Times: Updating Infective Endocarditis Diagnostic Criteria to Recognize Enterococcus faecalis as a Typical Endocarditis Bacterium. Clin Infect Dis. 2022;75(6):1097-102. doi:10.1093/cid/ciac181.

36. Durack DT, Lukes AS, Bright DK. Duke Endocarditis Service. New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Am J Med. 1994;96:200-9. doi:10.1016/0002-9343(94)90143-0.

37. Liesman RM, Pritt BS, Maleszewski JJ, Patel R. Laboratory Diagnosis of Infective Endocarditis. J Clin Microbiol. 2017;55:2599-608. doi:10.1128/JCM.00635-17.

38. Arvieux C, Common H. New diagnostic tools for prosthetic joint infection. Orthop Traumatol Surg Res. 2019;105(1S): S23-S30. doi:10.1016/j.otsr.2018.04.029.

39. Котова Е. О., Домонова Э. А., Кобалава Ж. Д. и др. Клинико-диагностическая ценность включения ПЦР-исследования крови в традиционный алгоритм идентификации возбудителей инфекционного эндокардита: когортное исследование 124 пациентов. Терапевтический архив. 2023;95(1):23-31. doi:10.26442/00403660.2023.01.202042.

40. Котова Е. О., Моисеева А. Ю., Кобалава Ж. Д. и др. Влияние антибактериальной терапии на чувствительность методов этиологической диагностики у оперированных пациентов с инфекционным эндокардитом. Рациональная Фармакотерапия в Кардиологии. 2023;19(1):34-42. doi:10.20996/1819-6446-2023-02-03.

41. Wahadat AR, Tanis W, Galema TW, et al. The impact of the multidisciplinary Endocarditis Team on the management of infective endocarditis. Neth Heart J. 2023;31(1):29-35. doi:10.1007/s12471-022-01707-6.

42. Ruch Y, Mazzucotelli JP, Lefebvre F, et al. Impact of Setting up an "Endocarditis Team" on the Management of Infective Endocarditis. Open Forum Infect Dis. 2019;6(9): ofz308. doi:10.1093/ofid/ofz308.

43. Van den Heuvel FMA, Bos M, Geuzebroek GSC, et al. The impact of implementing an endocarditis team in comparison to the classic heart team in a tertiary referral centre. BMC Cardiovasc Disord. 2022;22(1):114. doi:10.1186/s12872-022-02558-0.

44. Camou F, Dijos M, Barandon L, et al. Management of infective endocarditis and multidisciplinary approach. Med Mal Infect. 2019;49(1):17-22. doi:10.1016/j.medmal.2018.06.007.

45. Kaura A, Byrne J, Fife A, et al. Inception of the ‘endocarditis team’ is associated with improved survival in patients with infective endocarditis who are managed medically: findings from a before-and-after study. Open Heart. 2017;4(2): e000699. doi:10.1136/openhrt-2017-000699.

46. Shakya S, Hussain S, Gordon S, et al. Clinical Presentation of Infective Endocarditis in the Early 21st Century: A Descriptive Study. Open Forum Infect Dis. 2017;4: S559-S559. doi:10.1093/ofid/ofx163.1456.

47. Habib G, Lancellotti P, Erba P-A, et al. The ESC-EORP EURO-ENDO (European Infective Endocarditis) registry. Eur Hear J Qual Care Clin Outcomes. 2019;5:202-7. doi:10.1093/ehjqcco/qcz018.

48. Ducruet AF, Hickman ZL, Zacharia BE, et al. Intracranial infectious aneurysms: a comprehensive review. Neurosurg Rev. 2010;33:37. doi:10.1007/s10143-009-0233-1.

49. Snipsøyr MG, Ludvigsen M, Petersen E, et al. A systematic review of biomarkers in the diagnosis of infective endocarditis. Int J Cardiol. 2016;202:564-70. doi:10.1016/j.ijcard.2015.09.028.

50. Hu W, Su G, Zhu W, et al. Systematic Immune-Inflammation Index Predicts Embolic Events in Infective Endocarditis. Int Heart J. 2022;63(3):510-6. doi:10.1536/ihj.21-627.

51. Agus HZ, Kahraman S, Arslan C, et al. Systemic immune-inflammation index predicts mortality in infective endocarditis. J Saudi Heart Assoc. 2020;32(1):58-64. doi:10.37616/2212-5043.1010.

52. Котова Е. О., Моисеева А. Ю., Писарюк А. С. и др. Значение расчетных индексов воспаления для прогнозирования краткосрочной летальности у пациентов с инфекционным эндокардитом. Терапия. 2024;10(8S):180. EDN: FYFCDB.

53. Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: Guidelines from the American Heart Association. J Am Dent Assoc. 2007;138:739-60. doi:10.14219/jada.archive.2007.0262.

54. Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: Diagnosis, antimicrobial therapy, and management of complications: A scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015;132:1435-86. doi:10.1161/CIR.0000000000000296.

55. Lamy B, Dargère S, Arendrup MC, et al. How to Optimize the Use of Blood Cultures for the Diagnosis of Bloodstream Infections? A State-of-the Art. Front Microbiol. 2016;7:697. doi:10.3389/fmicb.2016.00697.

56. Котова Е. О., Домонова Э. А., Кобалава Ж. Д. и др. Современные тренды этиологической диагностики инфекционного эндокардита. Рациональная Фармакотерапия в Кардиологии. 2021;17(1):153-64. doi:10.20996/1819-6446-2021-02-14.

57. Котова Е. О., Домонова Э. А., Кобалава Ж. Д. и др. Инфекционный эндокардит неустановленной этиологии: возможности преодоления и роль микробиологистики. Кардиология. 2021;61(1):87-97. doi:10.18087/cardio.2021.1.n1218.

58. La Scola B, Raoult D. Direct Identification of Bacteria in Positive Blood Culture Bottles by Matrix-Assisted Laser Desorption Ionisation Time-of-Flight Mass Spectrometry. PLoS One. 2009;4: e8041. doi:10.1371/journal.pone.0008041.

59. Rodríguez-Sánchez B, Sánchez-Carrillo C, Ruiz A, et al. Direct identification of pathogens from positive blood cultures using matrix-assisted laser desorption-ionization timeof-flight mass spectrometry. Clin Microbiol Infect. 2014;20: O421-7. doi:10.1111/1469-0691.12455.

60. Burckhardt I, Zimmermann S. Susceptibility testing of bacteria using MALDI-ToF mass spectrometry. Front Microbiol. 2018;9:1744. doi:10.3389/fmicb.2018.01744.

61. Pecoraro AJK, Herbst PG, Pienaar C, et al. Modifed Duke/European Society of Cardiology 2015 clinical criteria for infective endocarditis: time for an update? Open Heart. 2022;9: e001856. doi:10.1136/openhrt2021-001856.

62. Kong WKF, Salsano A, Giacobbe DR, et al. Outcomes of culture-negative vs. culture-positive infective endocarditis: the ESC-EORP EURO-ENDO registry. Eur Heart J. 2022;43:2770-80. doi:10.1093/eurheartj/ehac307.

63. Котова Е. О., Домонова Э. А., Караулова Ю. Л. и др. Инфекционный эндокардит: значение молекулярно-биологических методов в этиологической диагностике. Терапевтический архив. 2016;88(11):62-7. doi:10.17116/terarkh2016881162-67.

64. Fournier PE, Gouriet F, Casalta JP, et al. Blood culture-negative endocarditis: Improving the diagnostic yield using new diagnostic tools. Medicine (Baltimore). 2017;96(47): e8392. doi:10.1097/MD.0000000000008392.

65. Fournier P, Thuny F, Richet H, et al. Comprehensive Diagnostic Strategy for Blood Culture-Negative Endocarditis: A Prospective Study of 819 New Cases. Clin Infect Dis. 2010;51:131-40. doi:10.1086/653675.

66. Tattevin P, Watt G, Revest M, et al. Update on blood culture-negative endocarditis. Médecine Mal Infect. 2015;45:1-8. doi:10.1016/j.medmal.2014.11.003.

67. Selton-Suty C, Maigrat CH, Devignes J, et al. Possible relationship between antiphospholipid antibodies and embolic events in infective endocarditis. Heart. 2018;104(6):509-16. doi:10.1136/heartjnl-2017-312359.

68. Loyens M, Thuny F, Grisoli D, et al. Link between endocarditis on porcine bioprosthetic valves and allergy to pork. Int J Cardiol. 2013;167:600-2. doi:10.1016/j.ijcard.2012.09.233.

69. Fillâtre P, Gacouin A, Revest M, et al. Determinants and consequences of positive valve culture when cardiac surgery is performed during the acute phase of infective endocarditis. Eur J Clin Microbiol Infect Dis. 2020;39:629-35. doi:10.1007/s10096-019-03764-z.

70. Fernández G, Álvarez B, Manzarbeitia F, Renedo G. Infective endocarditis at autopsy: A review of pathologic manifestations and clinical correlates. Medicine (Baltimore). 2012;91:152-64. doi:10.1097/MD.0b013e31825631ea.

71. Amat-Santos IJ, Messika-Zeitoun D, Eltchaninoff H, et al. Infective Endocarditis After Transcatheter Aortic Valve Implantation. Circulation. 2015;131:1566-74. doi:10.1161/CIRCULATIONAHA.114.014089.

72. Habib G, Badano L, Tribouilloy C, et al. Recommendations for the practice of echocardiography in infective endocarditis. Eur J Echocardiogr. 2010;11:202-19. doi:10.1093/ejechocard/jeq004.

73. Yuan XC, Liu M, Hu J, et al. Diagnosis of infective endocarditis using echocardiography. Med (United States). 2019;98. doi:10.1097/MD.0000000000017141.

74. Алехин М. Н., Рыбакова М. К., Сидоренко Б. А., Буткевич О. М. Значение эхокардиографии в диагностике инфекционного эндокардита. Кардиология. 2005:4-13.

75. Bai AD, Steinberg M, Showler A, et al. Diagnostic Accuracy of Transthoracic Echocardiography for Infective Endocarditis Findings Using Transesophageal Echocardiography as the Reference Standard: A Meta-Analysis. J Am Soc Echocardiogr. 2017;30:639-46. doi:10.1016/j.echo.2017.03.007.

76. Bonzi M, Cernuschi G, Solbiati M, et al. Diagnostic accuracy of transthoracic echocardiography to identify native valve infective endocarditis: a systematic review and meta-analysis. Intern Emerg Med. 2018;13:937-46. doi:10.1007/s11739-018-1831-0.

77. Erba PA, Pizzi MN, Roque A, et al. Multimodality imaging in infective endocarditis: an imaging team within the endocarditis team. Circulation. 2019;140:1753-65. doi:10.1161/CIRCULATIONAHA.119.040228.

78. Мацкеплишвили С. Т., Саидова М. А., Мироненко М. Ю. и др. Выполнение стандартной трансторакальной эхокардиографии. Методические рекомендации 2024. Российский кардиологический журнал. 2025;30(2):6271. doi:10.15829/1560-4071-2025-6271.

79. Afonso L, Kottam A, Reddy V, Penumetcha A. Echocardiography in Infective Endocarditis: State of the Art. Curr Cardiol Rep. 2017;19:1-13. doi:10.1007/s11886-017-0928-9.

80. Young WJ, Jeffery DA, Hua A, et al. Echocardiography in patients with infective endocarditis and the impact of diagnostic delays on clinical outcomes. Am J Cardiol. 2018;122:650-5. doi:10.1016/j.amjcard.2018.04.039.

81. Eudailey K, Lewey J, Hahn RT, George I. Aggressive infective endocarditis and the importance of early repeat echocardiographic imaging. J Thorac Cardiovasc Surg. 2014;147: e26-8. doi:10.1016/j.jtcvs.2013.10.069.

82. Ostergaard L, Vejlstrup N, Kober L, et al. Diagnostic potential of intracardiac echocardiography in patients with suspected prosthetic valve endocarditis. J Am Soc Echocardiogr. 2019;32:1558-64. doi:10.1016/j.echo.2019.06.016.

83. Incani A, Hair C, Purnell P, et al. Staphylococcus aureus bacteraemia: evaluation of the role of transoesophageal echocardiography in identifying clinically unsuspected endocarditis. Eur J Clin Microbiol Infect Dis. 2013;32:1003-8. doi:10.1007/s10096-013-1838-4.

84. Rasmussen RV, Host U, Arpi M, et al. Prevalence of infective endocarditis in patients with Staphylococcus aureus bacteraemia: the value of screening with echocardiography. Eur J Echocardiogr. 2011;12:414-20. doi:10.1093/ejechocard/jer023.

85. Ostergaard L, Bruun NE, Voldstedlund M, et al. Prevalence of infective endocarditis in patients with positive blood cultures: a Danish nationwide study. Eur Heart J. 2019;40:3237-44. doi:10.1093/eurheartj/ehz327.

86. Dahl A, Iversen K, Tonder N, et al. Prevalence of infective endocarditis in Enterococcus faecalis bacteremia. J Am Coll Cardiol. 2019;74:193-201. doi:10.1016/j.jacc.2019.04.059.

87. Koslow M, Kuperstein R, Eshed I, et al. The Unique Clinical Features and Outcome of Infectious Endocarditis and Vertebral Osteomyelitis Co-infection. Am J Med. 2014; 127:669. doi:10.1016/j.amjmed.2014.02.023.

88. Carbone A, Mouhat B, Philip M, et al. Spondylitis: A frequent and severe complication of infective endocarditis. Arch Cardiovasc Dis Suppl. 2020;12:82. doi:10.1016/j.acvdsp.2019.09.174.

89. Bruun NE, Habib G, Thuny F, Sogaard P. Cardiac imaging in infectious endocarditis. Eur Heart J. 2014;35:624-32. doi:10.1093/eurheartj/eht274.

90. Vieira M. Repeated echocardiographic examinations of patients with suspected infective endocarditis. Heart. 2004;90:1020-4. doi:10.1136/hrt.2003.025585.

91. Vallejo Camazon N, Cediel G, Nunez Aragon R, et al. Short- and long-term mortality in patients with left-sided infective endocarditis not undergoing surgery despite indication. Rev Esp Cardiol (Engl Ed). 2020;73:734-40. doi:10.1016/j.rec.2019.09.011.

92. Iversen K, Ihlemann N, Gill SU, et al. Partial oral versus intravenous antibiotic treatment of endocarditis. N Engl J Med. 2019;380:415-24. doi:10.1056/NEJMoa1808312.

93. Shapira Y, Weisenberg DE, Vaturi M, et al. The impact of intraoperative transesophageal echocardiography in infective endocarditis. Isr Med Assoc J. 2007;9:299-302.

94. MacKay EJ, Zhang B, Augoustides JG, et al. Association of intraoperative transesophageal echocardiography and clinical outcomes after open cardiac valve or proximal aortic surgery. JAMA Netw Open. 2022;5: e2147820. doi:10.1001/jamanetworkopen.2021.47820.

95. Berdejo J, Shibayama K, Harada K, et al. Evaluation of Vegetation Size and Its Relationship With Embolism in Infective Endocarditis. Circ Cardiovasc Imaging. 2014;7:149-54. doi:10.1161/CIRCIMAGING.113.000938.

96. Pfister R, Betton Y, ten Freyhaus H, et al. Three-dimensional compared to two-dimensional transesophageal echocardiography for diagnosis of infective endocarditis. Infection. 2016;44:725-31. doi:10.1007/s15010-016-0908-9.

97. Feuchtner GM, Stolzmann P, Dichtl W, et al. Multislice Computed Tomography in Infective Endocarditis. J Am Coll Cardiol. 2009;53:436-44. doi:10.1016/j.jacc.2008.01.077.

98. Rajani R, Klein JL. Infective endocarditis: A contemporary update. Clin Med J R Coll Physicians London. 2020;20:31-5. doi:10.7861/clinmed.cme.20.1.1.

99. Jain V, Wang TKM, Bansal A, et al. Diagnostic performance of cardiac computed tomography versus transesophageal echocardiography in infective endocarditis: a contemporary comparative meta-analysis. J Cardiovasc Comput Tomogr. 2021;15:313-21. doi:10.1016/j.jcct.2020.11.008.

100. Oliveira M, Guittet L, Hamon M, Hamon M. Comparative value of cardiac CT and transesophageal echocardiography in infective endocarditis: a systematic review and meta-analysis. Radiol Cardiothorac Imaging. 2020;2: e190189. doi:10.1148/ryct.2020190189.

101. Chaosuwannakit N, Makarawate P. Value of cardiac computed tomography angiography in pre-operative assessment of infective endocarditis. J Cardiothorac Surg. 2019;14:56. doi:10.1186/s13019-019-0880-4.

102. Fagman E, Flinck A, Snygg-Martin U, et al. Surgical decision-making in aortic prosthetic valve endocarditis: the infuence of electrocardiogram-gated computed tomography. Eur J Cardiothorac Surg. 2016;50:1165-71. doi:10.1093/ejcts/ezw177.

103. Georges H, Leroy O, Airapetian N, et al. Outcome and prognostic factors of patients with right-sided infective endocarditis requiring intensive care unit admission. BMC Infect Dis. 2018;18:85. doi:10.1186/s12879-018-2989-9.

104. Colen TW, Gunn M, Cook E, Dubinsky T. Radiologic manifestations of extra-cardiac complications of infective endocarditis. Eur Radiol. 2008;18:2433-45. doi:10.1007/s00330-008-1037-3.

105. Fagman E, Perrotta S, Bech-Hanssen O, et al. ECG-gated computed tomography: a new role for patients with suspected aortic prosthetic valve endocarditis. Eur Radiol. 2012;22:2407-14. doi:10.1007/s00330-012-2491-5.

106. Grob A, Thuny F, Villacampa C, et al. Cardiac multidetector computed tomography in infective endocarditis: a pictorial essay. Insights Imaging. 2014;5:559-70. doi:10.1007/s13244-014-0353-1.

107. Goddard A, Tan G, Becker J. Computed tomography angiography for the detection and characterization of intra-cranial aneurysms: Current status. Clin Radiol. 2005;60:1221-36. doi:10.1016/j.crad.2005.06.007.

108. Hekimian G, Kim M, Passefort S, et al. Preoperative use and safety of coronary angiography for acute aortic valve infective endocarditis. Heart 2010;96:696-700. doi:10.1136/hrt.2009.183772.

109. Lecomte R, Issa N, Gaborit B, et al. Risk-beneft assessment of systematic thoracoabdominal-pelvic computed tomography in infective endocarditis. Clin Infect Dis. 2019;69:1605-12. doi:10.1093/cid/ciz014.

110. Iung B, Tubiana S, Klein I, et al. Determinants of Cerebral Lesions in Endocarditis on Systematic Cerebral Magnetic Resonance Imaging. Stroke. 2013;44:3056-62. doi:10.1161/STROKEAHA.113.001470.

111. Goulenok T, Klein I, Mazighi M, et al. Infective Endocarditis with Symptomatic Cerebral Complications: Contribution of Cerebral Magnetic Resonance Imaging. Cerebrovasc Dis. 2013;35:327-36. doi:10.1159/000348317.

112. Hess A, Klein I, Iung B, et al. Brain MRI Findings in Neurologically Asymptomatic Patients with Infective Endocarditis. Am J Neuroradiol. 2013;34:1579-84. doi:10.3174/ajnr.A3582.

113. Chakraborty T, Scharf E, DeSimone D, et al. Variable signifcance of brain MRI fndings in infective endocarditis and its effect on surgical decisions. Mayo Clin Proc. 2019;94:1024-32. doi:10.1016/j.mayocp.2018.09.015.

114. Sotero FD, Rosario M, Fonseca AC, Ferro JM. Neurological complications of infective endocarditis. Curr Neurol Neurosci Rep. 2019;19:23. doi:10.1007/s11910-019-0935-x.

115. Haller S, Vernooij MW, Kuijer JPA, et al. Cerebral micro bleeds: imaging and clinical significance. Radiology. 2018;287:11-28. doi:10.1148/radiol.2018170803.

116. Duval X. Effect of Early Cerebral Magnetic Resonance Imaging on Clinical Decisions in Infective Endocarditis. Ann Intern Med. 2010;152:497. doi:10.7326/0003-4819-152-8-201004200-00006.

117. White PM, Teasdale EM, Wardlaw JM, Easton V. Intracranial Aneurysms: CT Angiography and MR Angiography for Detection — Prospective Blinded Comparison in a Large Patient Cohort. Radiology. 2001;219:739-49. doi:10.1148/radiology.219.3.r01ma16739.

118. Hui FK, Bain M, Obuchowski NA, et al. Mycotic aneurysm detection rates with cerebral angiography in patients with infective endocarditis. J Neurointerv Surg. 2015;7:449-52. doi:10.1136/neurintsurg-2014-011124.

119. Kim S-J, Pak K, Kim K, Lee JS. Comparing the diagnostic accuracies of F-18 fuorodeoxyglucose positron emission tomography and magnetic resonance imaging for the detection of spondylodiscitis: a meta-analysis. Spine (Phila Pa 1976) 2019;44:E414-E422. doi:10.1097/BRS.0000000000002861.

120. Foreman SC, Schwaiger BJ, Gempt J, et al. MR and CT imaging to optimize CT-guided biopsies in suspected spondylodiscitis. World Neurosurg. 2017;99:726-34. doi:10.1016/j.wneu.2016.11.017.

121. Palestro CJ, Brown ML, Forstrom L, et al. Society of Nuclear Medicine Procedure Guideline for 99mTc-Exametazime (HMPAO)-Labeled Leukocyte Scintigraphy for Suspected Infection/Inflammation. Soc Nucl Med Proced Guidel. 2004:1-6.

122. Rouzet F, Chequer R, Benali K, et al. Respective Performance of 18F-FDG PET and Radiolabeled Leukocyte Scintigraphy for the Diagnosis of Prosthetic Valve Endocarditis. J Nucl Med. 2014;55:1980-5. doi:10.2967/jnumed.114.141895.

123. Kircher M, Lapa C. Novel Noninvasive Nuclear Medicine Imaging Techniques for Cardiac Inflammation. Curr Cardiovasc Imaging Rep. 2017;10. doi:10.1007/s12410-017-9400-x.

124. Бокерия Л. А., Асланиди И. П., Пурсанова Д. М. и др. Диагностика электродного инфекционного эндокардита методом ПЭТ/КТ с 18F-фтордезоксиглюкозой. Анналы Аритмологии. 2019;16(1):22-7.

125. Mahmood M, Kendi AT, Ajmal S, et al. Meta-analysis of 18F-FDG PET/CT in the diagnosis of infective endocarditis. J Nucl Cardiol. 2019;26:922-35. doi:10.1007/s12350-017-1092-8.

126. Duval X, Le Moing V, Tubiana S, et al. Impact of systematic whole-body 18F-fuorodeoxyglucose PET/CT on the management of patients suspected of infective endocarditis: the prospective multicenter tepvendo study. Clin Infect Dis. 2021;73:393-403. doi:10.1093/cid/ciaa666.

127. Boursier C, Duval X, Bourdon A, et al. ECG-gated cardiac FDG PET acquisitions significantly improve detectability of infective endocarditis. JACC Cardiovasc Imaging. 2020;13:2691-3. doi:10.1016/j.jcmg.2020.06.036.

128. Erba PA, Conti U, Lazzeri E, et al. Added Value of 99mTc-HMPAO-Labeled Leukocyte SPECT/CT in the Characterization and Management of Patients with Infectious Endocarditis. J Nucl Med. 2012;53:1235-43. doi:10.2967/jnumed.111.099424.

129. Bensimhon L, Lavergne T, Hugonnet F, et al. Whole body [18F]fluorodeoxyglucose positron emission tomography imaging for the diagnosis of pacemaker or implantable cardioverter defibrillator infection: a preliminary prospective study. Clin Microbiol Infect. 2011;17:836-44. doi:10.1111/j.1469-0691.2010.03312.x.

130. Бокерия Л. А., Асланиди И. П., Пурсанова Д. М. и др. Возможности ПЭТ/КТ с 18F-фтордезоксиглюкозой в диагностике инфекционных процессов, связанных с имплантированными внутрисердечными устройствами. Бюллетень НЦССХ им. А. Н. Бакулева РАМН. Сердечно-сосудистые заболевания. 2019;20(6):498-508. doi:10.24022/1810-0694-2019-20-6-498-508.

131. Wang TKM, Sanchez-Nadales A, Igbinomwanhia E, et al. Diagnosis of infective endocarditis by subtype using (18) F-fuorodeoxyglucose positron emission tomography/computed tomography: a contemporary meta-analysis. Circ Cardiovasc Imaging. 2020;13:e010600. doi:10.1161/CIRCIMAGING.120.010600.

132. Голухова Е. З., Асланиди И. П., Пурсанова Д. М. и др. Возможности позитронно-эмиссионной томографии, совмещенной с компьютерной томографией, с 18F-фтордезоксиглюкозой в оценке распространенности инфекционного процесса у пациентов с подозрением на инфекционный эндокардит протезированного клапана. Креативная кардиология. 2020;14(3):245-54. doi:10.24022/1997-3187-2020-14-3-245-254.

133. Erba PA, Sollini M, Conti U, et al. Radiolabeled WBC Scintigraphy in the Diagnostic Workup of Patients With Suspected Device-Related Infections. JACC Cardiovasc Imaging. 2013;6:1075-86. doi:10.1016/j.jcmg.2013.08.001.

134. Kestler M, Munoz P, Rodriguez-Creixems M, et al. Role of (18) F-FDG PET in patients with infectious endocarditis. J Nucl Med. 2014;55:1093-8. doi:10.2967/jnumed.113.134981.

135. Vind SH, Hess S. Possible role of PET/CT in infective endocarditis. J Nucl Cardiol. 2010;17:516-9. doi:10.1007/s12350-009-9174-x.

136. Pigrau C, Almirante B, Flores X, et al. Spontaneous pyogenic vertebral osteomyelitis and endocarditis: Incidence, risk factors, and outcome. Am J Med. 2005;118:1287.e17-1287. doi:10.1016/j.amjmed.2005.02.027.

137. Tamura K. Clinical characteristics of infective endocarditis with vertebral osteomyelitis. J Infect Chemother. 2010;16:260-5. doi:10.1007/s10156-010-0046-8.

138. Дроздов Д. В., Макаров Л. М., Баркан В. С. и др. Регистрация электрокардиограммы покоя в 12 общепринятых отведениях взрослым и детям 2023. Методические рекомендации. Российский кардиологический журнал. 2023;28(10):5631. doi:10.15829/1560-4071-2023-5631.

139. Parra JA, Hernández L, Muñoz P, et al. Detection of spleen, kidney and liver infarcts by abdominal computed tomography does not affect the outcome in patients with left-side infective endocarditis. Med (United States). 2018;97:e11952. doi:10.1097/MD.0000000000011952.

140. Chou YH, Hsu CC, Tiu CM, Chang T. Splenic abscess: Sonographic diagnosis and percutaneous drainage or aspiration. Gastrointest Radiol. 1992;17:262-6. doi:10.1007/BF01888563.

141. Vahanian A, Alfieri O, Andreotti F, et al. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J. 2012;33:2451-96. doi:10.1093/eurheartj/ehs109.

142. Chambers J, Sandoe J, Ray S, et al. The infective endocarditis team: recommendations from an international working group. Heart. 2014;100(7):524-7. doi:10.1136/heartjnl-2013-304354.

143. Nunes MCP, Guimarães-Júnior MH, Murta Pinto PHO, et al. Outcomes of infective endocarditis in the current era: Early predictors of a poor prognosis. Int J Infect Dis. 2018;68:102-7. doi:10.1016/j.ijid.2018.01.016.

144. Pericàs JM, Llopis J, Jimenez-Exposito MJ, et al. Infective endocarditis in patients on chronic hemodialysis. J Am Coll Cardiol. 2021;77:1629-40. doi:10.1016/j.jacc.2021.02.014.

145. Gibbons EF, Huang G, Aldea G, et al. A multidisciplinary pathway for the diagnosis and treatment of infectious endocarditis. Crit Pathw Cardiol. 2020;19:187-94. doi:10.1097/HPC.0000000000000224.

146. Sambola A, Lozano-Torres J, Boersma E, et al. Predictors of embolism and death in left-sided infective endocarditis: the European Society of Cardiology EURObservational Research Programme European Infective Endocarditis registry. Eur Heart J. 2023;44(43):4566-75. doi:10.1093/eurheartj/ehad507.

147. Davierwala PM, Marin-Cuartas M, Misfeld M, Borger MA. The value of an "Endocarditis Team". Ann Cardiothorac Surg. 2019;8:621-9. doi:10.21037/acs.2019.09.03.

148. López J, Sevilla T, Vilacosta I, et al. Prognostic role of persistent positive blood cultures after initiation of antibiotic therapy in left-sided infective endocarditis. Eur Heart J. 2013;34:1749-54. doi:10.1093/eurheartj/ehs379.

149. Nashef SAM, Roques F, Sharples LD, et al. EuroSCORE II. Eur J Cardiothorac Surg. 2012;41:734-45. doi:10.1093/ejcts/ezs043.

150. Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation. 2005;111(23): e394-434. doi:10.1161/CIRCULATIONAHA.105.165564.

151. Gould FK, Denning DW, Elliott TS, et al. Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother. 2012;67(2):269-89. doi:10.1093/jac/dkr450.

152. Nordström L, Ringbert H, Cronberg S, et al. Does administration of an aminoglycoside in a single daily dose affect its efficacy and toxicity? J Antimicrob Chemother. 1990;25:159-73. doi:10.1093/jac/25.1.159.

153. Lebeaux D, Fernández-Hidalgo N, Pilmis B, et al. Aminoglycosides for infective endocarditis: time to say goodbye? Clin Microbiol Infect. 2020;26:723-8. doi:10.1016/j.cmi.2019.10.017.

154. Cosgrove SE, Vigliani GA, Campion M, et al. Initial Low‐Dose Gentamicin for Staphylococcus aureus Bacteremia and Endocarditis Is Nephrotoxic. Clin Infect Dis. 2009;48:713-21. doi:10.1086/597031.

155. Cremieux AC, Maziere B, Vallois JM, et al. Evaluation of Antibiotic Diffusion into Cardiac Vegetations by Quantitative Autoradiography. J Infect Dis. 1989;159:938-44. doi:10.1093/infdis/159.5.938.

156. Coste A, Poinot M, Panaget S, et al. Use of rifampicin and graft removal are associated with better outcomes in prosthetic vascular graft infection. Infection. 2021;49(1):127-33. doi:10.1007/s15010-020-01551-z.

157. Suzuki H, Pandya A, Hasegawa S, Tholany J. Association between adjunctive rifampin and gentamicin use and outcomes for patients with staphylococcal prosthetic valve endocarditis: a propensity-score adjusted retrospective cohort study. Infection. 2025;53(2):607-14. doi:10.1007/s15010-024-02421-8.

158. Veganzones J, Montero A, Maseda E. New evidence on the use of fosfomycin for bacteremia and infectious endocarditis. Rev Esp Quimioter. 2019;32:25-9.

159. Fowler VG, Boucher HW, Corey GR, et al. Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus. N Engl J Med. 2006;355:653-65. doi:10.1056/NEJMoa053783.

160. Miró JM, Entenza JM, del Río A, et al. High-Dose Daptomycin plus Fosfomycin Is Safe and Effective in Treating Methicillin-Susceptible and Methicillin-Resistant Staphylococcus aureus Endocarditis. Antimicrob Agents Chemother. 2012;56:4511-5. doi:10.1128/AAC.06449-11.

161. Shaw E, Miró JM, Puig-Asensio M, et al. Daptomycin plus fosfomycin versus daptomycin monotherapy in treating MRSA: Protocol of a multicentre, randomised, phase III trial. BMJ Open. 2015;5(3): e006723. doi:10.1136/bmjopen-2014-006723.

162. Grillo S, Cuervo G, Carratalà J, et al. Impact of β-Lactam and Daptomycin Combination Therapy on Clinical Outcomes in Methicillin-susceptible Staphylococcus aureus Bacteremia: A Propensity Score-matched Analysis. Clin Infect Dis. 2019;69:1480-8. doi:10.1093/cid/ciz018.

163. Francioli P, Ruch W, Stamboulian D. Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone and netilmicin for 14 Days: A prospective multicenter study. Clin Infect Dis. 1995;21:1406-10. doi:10.1093/clinids/21.6.1406.

164. Определение чувствительности микроорганизмов к антимикробным препаратам. Российские рекомендации. Версия 2024-02. Год утверждения (частота пересмотра): 2024 (пересмотр ежегодно). МАКМАХ, СГМУ: Смоленск, 2024. 192 с. ISBN: 978-5-91812-253-2.

165. Ritchie BM, Hirning BA, Stevens CA, et al. Risk factors for acute kidney injury associated with the treatment of bacterial endocarditis at a tertiary academic medical center. J Chemother. 2017;29:292-8. doi:10.1080/1120009X.2017.1296916.

166. Majumdar A, Chowdhary S, Ferreira MA, et al. Renal pathological findings in infective endocarditis. Nephrol Dial Transplant. 2000;15:1782-7. doi:10.1093/ndt/15.11.1782.

167. Povalyaev N, Pisaryuk A, Sorokina M, et al. Renal pathologic findings and clinical associations in patients with infective endocarditis. European Heart Journal. 2019:40(S1);81. doi:10.1093/eurheartj/ehz745.0081.

168. Pisaryuk A, Povalyaev N, Sorokina M, et al. Acute kidney injury risk calculator in patients with infective endocarditis. European Heart Journal. 2019;40(S1):1072. doi:10.1093/eurheartj/ehz748.1072.

169. Pisaryuk A, Povalyaev N, Sorokina M, et al. Value of biomarkers (urinary KIM-1, NGAL, albumin, serum Cys C) for predicting renal lesions and prognosis in patients with infective endocarditis. European Heart Journal. 2019:40(S1);1076. doi:10.1093/eurheartj/ehz748.1076.

170. Pisaryuk A, Povalyaev N, Sorokina M, et al. Prevalence, clinical features and outcomes of acute kidney disease in infective endocarditis. Nephrology Dialysis Transplantation. 2019;34(Supplement_1): gfz103.SP246. doi:10.1093/ndt/gfz103.SP246.

171. del Río A, Anguera I, Miró JM, et al. Surgical Treatment of Pacemaker and Defibrillator Lead Endocarditis. Chest. 2003;124:1451-9. doi:10.1378/chest.124.4.1451.

172. Francioli P, Etienne J, Hoigné R, et al. Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone sodium for 4 weeks. Efficacy and outpatient treatment feasibility. JAMA. 1992;267(2):264-7. doi:10.1001/jama.1992.03480020074034.

173. Martino P, Venditti M, Micozzi A, et al. Teicoplanin in the treatment of gram-positivebacterial endocarditis. Antimicrob Agents Chemother. 1989;33:1329-34. doi:10.1128/AAC.33.8.1329.

174. Lewis PJ, Martino P, Mosconi G, Harding I. Teicoplanin in endocarditis: A multicentre, open European study. Chemotherapy. 1995;41:399-411. doi:10.1159/000239373.

175. Brett MS. Emergence of a high-level cefotaxime-resistant Streptococcus pneumoniae strain in New Zealand. J Med Microbiol. 2001;50:173-6. doi:10.1099/0022-1317-50-2-173.

176. Martínez E, Miró JM, Almirante B, et al. Effect of Penicillin Resistance of Streptococcus pneumoniae on the Presentation, Prognosis, and Treatment of Pneumococcal Endocarditis in Adults. Clin Infect Dis. 2002;35:130-9. doi:10.1086/341024.

177. Sambola A, Miro JM, Tornos MP, et al. Streptococcus agalactiae Infective Endocarditis: Analysis of 30 Cases and Review of the Literature, 1962-1998. Clin Infect Dis. 2002;34:1576-84. doi:10.1086/340538.

178. Gavaldà J, Pahissa A, Almirante B, et al. Effect of gentamicin dosing interval on therapy of viridans streptococcal experimental endocarditis with gentamicin plus penicillin. Antimicrob Agents Chemother. 1995;39(9):2098-103. doi:10.1128/AAC.39.9.2098.

179. Giuliano S, Caccese R, Carfagna P, et al. Endocarditis caused by nutritionally variant streptococci: A case report and literature review. Infez Med. 2012;20:67-74.

180. Adam EL, Siciliano RF, Gualandro DM, et al. Case series of infective endocarditis caused by Granulicatella species. Int J Infect Dis. 2015;31:56-8. doi:10.1016/j.ijid.2014.10.023.

181. Martí-Carvajal AJ, Dayer M, Conterno LO, et al. A comparison of different antibiotic regimens for the treatment of infective endocarditis. Cochrane Database Syst Rev. 2020;2020. doi:10.1002/14651858.CD009880.pub3.

182. Fortún J, Navas E, Martínez‐Beltrán J, et al. Short‐Course Therapy for Right‐Side Endocarditis Due to Staphylococcus aureus in Drug Abusers: Cloxacillin versus Glycopeptides in Combination with Gentamicin. Clin Infect Dis. 2001;33:120-5. doi:10.1086/320869.

183. DiNubile MJ. Short-course antibiotic therapy for right-sided endocarditis caused by Staphylococcus aureus in injection drug users. Ann Intern Med. 1994;121:873-6. doi:10.7326/0003-4819-121-11-199412010-00009.

184. Smith JR, Claeys KC, Barber KE, Rybak MJ. High-Dose Daptomycin Therapy for Staphylococcal Endocarditis and When to Apply It. Curr Infect Dis Rep. 2014;16. doi:10.1007/s11908-014-0429-6.

185. Guleri A, Utili R, Dohmen P, et al. Daptomycin for the Treatment of Infective Endocarditis: Results from European Cubicin® Outcomes Registry and Experience (EU-CORE). Infect Dis Ther. 2015;4:283-96. doi:10.1007/s40121-015-0075-9.

186. Tissot-Dupont H, Gouriet F, Oliver L, et al. High-dose trimethoprim-sulfamethoxazole and clindamycin for Staphylococcus aureus endocarditis. Int J Antimicrob Agents. 2019;54:143-8. doi:10.1016/j.ijantimicag.2019.06.006.

187. Taha L, Stegger M, Söderquist B. Staphylococcus lugdunensis: antimicrobial susceptibility and optimal treatment options. Eur J Clin Microbiol Infect Dis. 2019;38:1449-55. doi:10.1007/s10096-019-03571-6.

188. Siciliano RF, Randi BA, Gualandro DM, et al. Early-onset prosthetic valve endocarditis definition revisited: Prospective study and literature review. Int J Infect Dis. 2018;67:3-6. doi:10.1016/j.ijid.2017.09.004.

189. Sader HS, Carvalhaes CG, Mendes RE. Ceftaroline activity against Staphylococcus aureus isolated from patients with infective endocarditis, worldwide (2010-2019). Int J Infect Dis. 2021;102:524-8. doi:10.1016/j.ijid.2020.11.130.

190. Zasowski EJ, Trinh TD, Claeys KC, et al. Multicenter cohort study of ceftaroline versus daptomycin for treatment of methicillin-resistant Staphylococcus aureus bloodstream infection. Open Forum Infect Dis. 2022;9: ofab606. doi:10.1093/ofid/ofab606.

191. Nadrah K, Strle F. Antibiotic Combinations with Daptomycin for Treatment of Staphylococcus aureus Infections. Chemother Res Pract. 2011;2011:619321. doi:10.1155/2011/619321.

192. Casapao AM, Davis SL, McRoberts JP, et al. Evaluation of vancomycin population susceptibility analysis profile as a predictor of outcomes for patients with infective endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2014;58:4636-41. doi:10.1128/AAC.02820-13.

193. Сhen M, Lee C, Gnyra M, Wong M. Vancomycin area under the curve/minimum inhibitory concentration and trough level concordance-evaluation on an urban health unit. Ther Adv Infect Dis. 2022;9:20499361221140368.

194. Matsumoto K, Oda K, Shoji K, et al. Clinical Practice Guidelines for Therapeutic Drug Monitoring of Vancomycin in the Framework of Model-Informed Precision Dosing: A Consensus Review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. Pharmaceutics. 2022;14(3):489.

195. Holland TL, Cosgrove SE, Doernberg SB, et al.; ERADICATE Study Group. Ceftobiprole for Treatment of Complicated Staphylococcus aureus Bacteremia. N Engl J Med. 202;389(15):1390-401. doi:10.1056/NEJMoa2300220.

196. Bavaro DF, Belati A, Bussini L, et al. Safety and effectiveness of fifth generation cephalosporins for the treatment of methicillin-resistant staphylococcus aureus bloodstream infections: a narrative review exploring past, present, and future. Expert Opin Drug Saf. 2024;23(1):9-36. doi:10.1080/14740338.2023.2299377.

197. Dhand A, Bayer AS, Pogliano J, et al. Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillinresistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin Infect Dis. 2011;53:158-63. doi:10.1093/cid/cir340.

198. Pericàs JM, Moreno A, Almela M, et al. Efficacy and safety of fosfomycin plus imipenem versus vancomycin for complicated bacteraemia and endocarditis due to methicillinresistant Staphylococcus aureus: a randomized clinical trial. Clin Microbiol Infect. 2018;24:673-6. doi:10.1016/j.cmi.2018.01.010.

199. Watkins RR, Lemonovich TL, File TM. An evidence-based review of linezolid for the treatment of methicillin-resistant Staphylococcus aureus (MRSA): Place in therapy. Core Evid. 2012;7:131-43. doi:10.2147/CE.S33430.

200. Jang H, Kim S, Kim KH, et al. Salvage Treatment for Persistent Methicillin‐Resistant Staphylococcus aureus Bacteremia: Efficacy of Linezolid With or Without Carbapenem. Clin Infect Dis. 2009;49:395-401. doi:10.1086/600295.

201. Berrington A. Treatment of endocarditis using moxifloxacin. Int J Med Microbiol. 2001;291:237-9. doi:10.1078/1438-4221-00126.

202. Tong SYC, Lye DC, Yahav D, et al.; Australasian Society for Infectious Diseases Clinical Research Network. Effect of Vancomycin or Daptomycin With vs Without an Antistaphylococcal β-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA Bacteremia: A Randomized Clinical Trial. JAMA. 2020;323(6):527-37. doi:10.1001/jama.2020.0103.

203. Casalta JP, Zaratzian C, Hubert S, et al. Treatment of Staphylococcus aureus endocarditis with high doses of trimethoprim/sulfamethoxazole and clindamycin-Preliminary report. Int J Antimicrob Agents. 2013;42(2):190-1. doi:10.1016/j.ijantimicag.2013.05.002.

204. Entenza JM, Que YA, Vouillamoz J, et al. Efficacies of Moxifloxacin, Ciprofloxacin, and Vancomycin against Experimental Endocarditis Due to Methicillin-Resistant Staphylococcus aureus Expressing Various Degrees of Ciprofloxacin Resistance. Antimicrob Agents Chemother. 2001;45:3076-83. doi:10.1128/AAC.45.11.3076-3083.2001.

205. Nigo M, Munita JM, Arias CA, Murray BE. What’s New in the Treatment of Enterococcal Endocarditis? Curr Infect Dis Rep. 2014;16:431. doi:10.1007/s11908-014-0431-z.

206. Beganovic M, Luther MK, Rice LB, et al. A Review of Combination Antimicrobial Therapy for Enterococcus faecalis Bloodstream Infections and Infective Endocarditis. Clin Infect Dis. 2018;67(2):303-9. doi:10.1093/cid/ciy064.

207. Miro JM, Pericas JM, Del Rio A. A new era for treating enterococcus faecalis endocarditis ampicillin plus short-course gentamicin or ampicillin plus ceftriaxone: That is the question! Circulation. 2013;127:1763-6. doi:10.1161/CIRCULATIONAHA.113.002431.

208. Falcone M, Russo A, Venditti M. Optimizing antibiotic therapy of bacteremia and endocarditis due to staphylococci and enterococci: New insights and evidence from the literature. J Infect Chemother. 2015;21:330-9. doi:10.1016/j.jiac.2015.02.012.

209. Herrera-Hidalgo L, Lomas-Cabezas JM, López-Cortés LE, et al. Ampicillin Plus Ceftriaxone Combined Therapy for Enterococcus faecalis Infective Endocarditis in OPAT. J Clin Med. 2021;11(1):7. doi:10.3390/jcm11010007.

210. Pericas JM, Cervera C, del Rio A, et al. Changes in the treatment of Enterococcus faecalis infective endocarditis in Spain in the last 15 years: from ampicillin plus gentamicin to ampicillin plus ceftriaxone. Clin Microbiol Infect. 2014;20(12): O1075-83. doi:10.1111/1469-0691.12756.

211. Antonello RM, Canetti D, Riccardi N. Daptomycin synergistic properties from in vitro and in vivo studies: a systematic review. J Antimicrob Chemother. 2022;78(1):52-77. doi:10.1093/jac/dkac346.

212. Pontikis K, Pefanis A, Tsaganos T, et al. Efficacy of tigecycline alone and in combination with gentamicin in the treatment of experimental endocarditis due to linezolid-resistant Enterococcus faecium. Antimicrob Agents Chemother. 2013;57:3392-4. doi:10.1128/AAC.00646-13.

213. Coburn B, Toye B, Rawte P, et al. Antimicrobial susceptibilities of clinical isolates of HACEK organisms. Antimicrob Agents Chemother. 2013;57:1989-91. doi:10.1128/AAC.00111-13.

214. Choi HN, Park KH, Park S, et al. Prosthetic valve endocarditis caused by HACEK organisms: A case report and systematic review of the literature. Infect Chemother. 2017;49:282-5. doi:10.3947/ic.2017.49.4.282.

215. Das M, Badley AD, Cockerill FR, et al. Infective endocarditis caused by HACEK microorganisms. Annu Rev Med. 1997;48:25-33. doi:10.1146/annurev.med.48.1.25.

216. Paturel L, Casalta JP, Habib G, et al. Actinobacillus actinomycetemcomitans endocarditis. Clinical Microbiology and Infection. 2004;10:98-118. doi:10.1111/j.1469-0691.2004.00794.x

217. Durante-Mangoni E, Tripodi MF, Albisinni R, Utili R. Management of Gramnegative and fungal endocarditis. Int J Antimicrob Agents. 2010;36. doi:10.1016/j.ijantimicag.2010.11.012.

218. Ertugrul Mercan M, Arslan F, Ozyavuz Alp S, et al. Non-HACEK Gram-negative bacillus endocarditis. Med Mal Infect. 2019;49:616-20. doi:10.1016/j.medmal.2019.03.013.

219. Steinbach WJ, Perfect JR, Cabell CH, et al. A meta-analysis of medical versus surgical therapy for Candida endocarditis. J Infect. 2005;51:230-47. doi:10.1016/j.jinf.2004.10.016.

220. Elahi MW, Huang E, Kumar V, et al. Prosthetic Aortic Valve Endocarditis Due to Candida glabrata Successfully Treated With Intravenous Micafungin Followed by Oral Fluconazole Without Surgery: A Case Report and Literature Review. Cureus. 2025;17(2):e79550. doi:10.7759/cureus.79550.

221. Cornely OA, Lasso M, Betts R, et al. Caspofungin for the treatment of less common forms of invasive candidiasis. J Antimicrob Chemother. 2007;60:363-9. doi:10.1093/jac/dkm169.

222. Tattevin P, Revest M, Lefort A, et al. Fungal endocarditis: current challenges. Int J Antimicrob Agents. 2014;44:290-4. doi:10.1016/j.ijantimicag.2014.07.003.

223. Ahuja T, Fong K, Louie E. Combination antifungal therapy for treatment of Candida parapsilosis prosthetic valve endocarditis and utility of T2Candida Panel®: A case series. IDCases 2019;15: e00525. doi:10.1016/j.idcr.2019.e00525.

224. Gardiner BJ, Slavin MA, Korman TM, Stuart RL. Hampered by historical paradigms — echinocandins and the treatment of Candida endocarditis. Mycoses. 2014;57:316-9. doi:10.1111/MYC.12154.

225. Reyes HA, Carbajal WH, Valdez LM, Lozada C. Successful medical treatment of infective endocarditis caused by Candida parapsilosis in an immunocompromised patient. BMJ Case Rep. 2015;2015. doi:10.1136/BCR-2015-212128.

226. Bezerra LS, Silva JA, Santos-Veloso MA, et al. Antifungal Efficacy of Amphotericin B in Candida Albicans Endocarditis Therapy: Systematic Review. Brazilian J Cardiovasc Surg. 2020:1-8. doi:10.21470/1678-9741-2019-0159.

227. Reis LJ, Barton TD, Pochettino A, et al. Successful Treatment of Aspergillus Prosthetic Valve Endocarditis with Oral Voriconazole. Clin Infect Dis. 2005;41:752-3. doi:10.1086/432580.

228. Lennard K, Bannan A, Grant P, Post J. Potential benefit of combination antifungal therapy in Aspergillus endocarditis. BMJ Case Rep. 2020;13: e234008. doi:10.1136/bcr-2019-234008.

229. Pericàs JM, Llopis J, González-Ramallo V, et al. Outpatient Parenteral Antibiotic Treatment for Infective Endocarditis: A Prospective Cohort Study From the GAMES Cohort. Clin Infect Dis. 2019;69:1690-700. doi:10.1093/cid/ciz030.

230. Aksoy O, Sexton DJ, Wang A, et al. Early Surgery in Patients with Infective Endocarditis: A Propensity Score Analysis. Clin Infect Dis. 2007;44:364-72. doi:10.1086/510583.

231. Pries-Heje MM, Wiingaard C, Ihlemann N, et al. Five-Year Outcomes of the Partial Oral Treatment of Endocarditis (POET) Trial. N Engl J Med. 2022;386(6):601-2. doi:10.1056/NEJMc2114046.

232. García-Cabrera E, Fernández-Hidalgo N, Almirante B, et al. Neurological Complications of Infective Endocarditis. Circulation. 2013;127:2272-84. doi:10.1161/CIRCULATIONAHA.112.000813.

233. Fernández-Hidalgo N, Almirante B, Tornos P, et al. Immediate and long-term outcome of left-sided infective endocarditis. A 12-year prospective study from a contemporary cohort in a referral hospital. Clin Microbiol Infect. 2012;18: E522-30. doi:10.1111/1469-0691.12033.

234. Ong E, Mechtouff L, Bernard E, et al. Thrombolysis for stroke caused by infective endocarditis: an illustrative case and review of the literature. J Neurol. 2013;260:1339-42. doi:10.1007/s00415-012-6802-1.

235. Connolly DL, Choudhury A, Davis RC, Lip GYH. A randomized trial of aspirin on the risk of embolic events in patients with infective endocarditis. J Am Coll Cardiol. 2004;43:1134-5. doi:10.1016/j.jacc.2003.12.025.

236. Kupferwasser LI, Yeaman MR, Shapiro SM, et al. Acetylsalicylic Acid Reduces Vegetation Bacterial Density, Hematogenous Bacterial Dissemination, and Frequency of Embolic Events in Experimental Staphylococcus aureus Endocarditis Through Antiplatelet and Antibacterial Effects. Circulation. 1999;99:2791-7. doi:10.1161/01.CIR.99.21.2791.

237. Anavekar NS, Tleyjeh IM, Anavekar NS, et al. Impact of Prior Antiplatelet Therapy on Risk of Embolism in Infective Endocarditis. Clin Infect Dis. 2007;44:1180-6. doi:10.1086/513197.

238. Habib A, Irfan M, Baddour LM, et al. Impact of prior aspirin therapy on clinical manifestations of cardiovascular implantable electronic device infections. Europace. 2013;15:227-35. doi:10.1093/europace/eus292.

239. Chan K-L, Tam J, Dumesnil JG, et al. Effect of Long-Term Aspirin Use on Embolic Events in Infective Endocarditis. Clin Infect Dis. 2008;46:37-41. doi:10.1086/524021.

240. Snygg-Martin U, Rasmussen RV, Hassager C, et al. The relationship between cerebrovascular complications and previously established use of antiplatelet therapy in leftsided infective endocarditis. Scand J Infect Dis. 2011:899-904.

241. Pettersson GB, Coselli JS, Pettersson GB, et al. 2016 The American Association for Thoracic Surgery (AATS) consensus guidelines: Surgical treatment of infective endocarditis: Executive summary. J Thorac Cardiovasc Surg. 2017;153:1241-58. doi:10.1016/j.jtcvs.2016.09.093.

242. Thuny F, Beurtheret S, Mancini J, et al. The timing of surgery influences mortality and morbidity in adults with severe complicated infective endocarditis: a propensity analysis. Eur Heart J. 2011;32:2027-33. doi:10.1093/eurheartj/ehp089.

243. Yucel E, Bearnot B, Paras ML, et al. Diagnosis and Management of Infective Endocarditis in People Who Inject Drugs: JACC State-of-the-Art Review. J Am Coll Cardiol. 2022;79(20):2037-57. doi:10.1016/j.jacc.2022.03.349.

244. Javorski MJ, Rosinski BF, Shah S, et al. Infective Endocarditis in Patients Addicted to Injected Opioid Drugs. J Am Coll Cardiol. 2024;83(8):811-23. doi:10.1016/j.jacc.2023.12.016.

245. Wurcel AG, Zubiago J, Reyes J, et al. Surgeons’ Perspectives on Valve Surgery in People With Drug Use-Associated Infective Endocarditis. Ann Thorac Surg. 2023;116(3):492-8. doi:10.1016/j.athoracsur.2021.12.068.

246. Alnabelsi TS, Sinner G, Al-Abdouh A, et al. The Evolving Trends in Infective Endocarditis and Determinants of Mortality: a 10-year Experience From a Tertiary Care Epicenter. Curr Probl Cardiol. 2023;48(6):101673. doi:10.1016/j.cpcardiol.2023.101673.

247. Marinacci LX, Li A, Tsay A, et al. Readmissions Among Patients With Surgically Managed Drug Use Associated-Infective Endocarditis Before and After the Implementation of an Addiction Consult Team: A Retrospective, Observational Analysis. J Addict Med. 2024;18(5):586-94. doi:10.1097/ADM.0000000000001368.

248. Liang F, Song B, Liu R, et al. Optimal timing for early surgery in infective endocarditis: a meta-analysis. Interact Cardiovasc Thorac Surg. 2016;22(3):336-45. doi:10.1093/icvts/ivv368.

249. Демин А. А., Кобалава Ж. Д., Скопин И. И. и др. Инфекционный эндокардит и инфекция внутрисердечных устройств. Клинические рекомендации 2021. Российский кардиологический журнал. 2022;27(10):5233. doi:10.15829/1560-4071-2022-5233.

250. Lozano Ibañez A, Pulido P, López Díaz J, et al. Native Valve Infective Endocarditis with Severe Regurgitation: What Matters Is Heart Failure. J Clin Med. 2024;13(20):6222. doi:10.3390/jcm13206222.

251. Bohbot Y, Habib G, Laroche C, et al. Characteristics, management, and outcomes of patients with left-sided infective endocarditis complicated by heart failure: a substudy of the ESC-EORP EURO-ENDO (European infective endocarditis) registry. Eur J Heart Fail. 2022;24(7):1253-65. doi:10.1002/ejhf.2525.

252. Gierlinger G, Sames-Dolzer E, Kreuzer M, et al. Surgical therapy of infective endocarditis following interventional or surgical pulmonary valve replacement. Eur J Cardiothorac Surg. 2021;59(6):1322-8. doi:10.1093/ejcts/ezab086.

253. Yokoyama Y, Goto T. Midterm outcomes of early versus late surgery for infective endocarditis with neurologic complications: a meta-analysis. J Cardiothorac Surg. 2021;16(1):49. doi:10.1186/s13019-021-01425-x.

254. Beaini H, Chunawala Z, Cheeran D, et al. Cardiogenic Shock: Focus on Non-Cardiac Biomarkers. Curr Heart Fail Rep. 2024;21(6):604-14. doi:10.1007/s11897-024-00676-8.

255. Pazdernik M, Iung B, Mutlu B, et al. Surgery and outcome of infective endocarditis in octogenarians: prospective data from the ESC EORP EURO-ENDO registry. Infection. 2022;50(5):1191-202. doi:10.1007/s15010-022-01792-0.

256. Zhu L, Liu J, Zhao H. A clinical classification method with outstanding advantages for quickly identifying hazardous types: Letter regarding the article ‘Acute heart failure congestion and perfusion status — impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry’. Eur J Heart Fail. 2024;26(12):2616-7. doi:10.1002/ejhf.3479.

257. Schupp T, Behnes M, Rusnak J, et al. Predictors and Prognostic Impact of Early Acute Kidney Injury in Cardiogenic Shock: Results from a Monocentric, Prospective Registry. Cardiorenal Med. 2024;14(1):81-93. doi:10.1159/000533975.

258. Kiefer T, Park L, Tribouilloy C, et al. Association between valvular surgery and mortality among patients with infective endocarditis complicated by heart failure. JAMA. 2011;306(20):2239-47. doi:10.1001/jama.2011.1701.

259. Pericàs JM, Hernández-Meneses M, Muñoz P, et al. Characteristics and Outcome of Acute Heart Failure in Infective Endocarditis: Focus on Cardiogenic Shock. Clin Infect Dis. 2021;73(5):765-74. doi:10.1093/cid/ciab098.

260. Beer BN, Kellner C, Sundermeyer J, et al. Prediction of cardiac worsening through to cardiogenic shock in patients with acute heart failure. ESC Heart Fail. 2024;11(4):2249-58. doi:10.1002/ehf2.14792.

261. Yang B, Caceres J, Farhat L, et al. Root abscess in the setting of infectious endocarditis: Short- and long-term outcomes. J Thorac Cardiovasc Surg. 2021;162(4):1049-59. doi:10.1016/j.jtcvs.2019.12.140.

262. Harris WM, Sinha S, Caputo M, et al. Surgical outcomes and optimal approach to treatment of aortic valve endocarditis with aortic root abscess — systematic review and meta-analysis. Perfusion. 2024;39(2):256-65. doi:10.1177/02676591221137484.

263. Cresti A, Baratta P, De Sensi F, et al. Clinical Features and Mortality Rate of Infective Endocarditis in Intensive Care Unit: A Large-Scale Study and Literature Review. Anatol J Cardiol. 2024;28(1):44-54. doi:10.14744/AnatolJCardiol.2023.3463.

264. Ojha N, Dhamoon AS. Fungal Endocarditis. [Updated 2022 Jul 29]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-.

265. Pasha AK, Lee JZ, Low SW, et al. Fungal Endocarditis: Update on Diagnosis and Management. Am J Med. 2016;129(10):1037-43. doi:10.1016/j.amjmed.2016.05.012.

266. Lee SJ, Jeon D, Cho WH, Kim YS. The Clinical Impacts of Apparent Embolic Event and the Predictors of In-Hospital Mortality in Patients with Infective Endocarditis. J Korean Med Sci. 2014;29:1646. doi:10.3346/jkms.2014.29.12.1646.

267. Wojda TR, Cornejo K, Lin A, et al. Septic Embolism: A Potentially Devastating Complication of Infective Endocarditis. In; Firstenberg M. S. Contemporary Challenges in Endocarditis. London: IntechOpen; 2016. 178 p. ISBN: 978-953-51-2770-3. doi:10.5772/62550.

268. Hermanns H, Alberts T, Preckel B, el al. Perioperative Complications in Infective Endocarditis. J Clin Med. 2023;12(17):5762. doi:10.3390/jcm12175762.

269. Dickerman SA, Abrutyn E, Barsic B, et al. The relationship between the initiation of antimicrobial therapy and the incidence of stroke in infective endocarditis: An analysis from the ICE Prospective Cohort Study (ICE-PCS). Am Heart J. 2007;154:1086-94. doi:10.1016/j.ahj.2007.07.023.

270. Yang A, Tan C, Adhikari NKJ, et al. Time-sensitive predictors of embolism in patients with left-sided endocarditis: Cohort study. PLoS One. 2019;14(4): e0215924. doi:10.1371/journal.pone.0215924.

271. Dashkevich A, Bratkov G, Li Y, et al. Impact of Operative Timing in Infective Endocarditis with Cerebral Embolism-The Risk of Intermediate Deterioration. J Clin Med. 2021;10(10):2136. doi:10.3390/jcm10102136.

272. Saha S, Dudakova A, Danner BC, et al. Bacterial Spectrum and Infective Foci in Patients Operated for Infective Endocarditis: Time to Rethink Strategies? Thorac Cardiovasc Surg. 2023;71(1):2-11. doi:10.1055/s-0041-1740540.

273. Weber C, Misfeld M, Diab M, et al. Infective endocarditis and spondylodiscitis-impact of sequence of surgical therapy on survival and recurrence rate. Eur J Cardiothorac Surg. 2024;66(1): ezae246. doi:10.1093/ejcts/ezae246.

274. Hijazi MM, Siepmann T, El-Battrawy I, et al. The impact of concomitant infective endocarditis in patients with spondylodiscitis and isolated spinal epidural empyema and the diagnostic accuracy of the modified duke criteria. Front Surg. 2024;10:1333764. doi:10.3389/fsurg.2023.1333764.

275. Mir T, Uddin M, Qureshi WT, et al. Predictors of Complications Secondary to Infective Endocarditis and Their Associated Outcomes: A Large Cohort Study from the National Emergency Database (2016-2018). Infect Dis Ther. 2022;11(1):305-21. doi:10.1007/s40121-021-00563-y.

276. Bui JT, Schranz AJ, Strassle PD, et al. Pulmonary complications observed in patients with infective endocarditis with and without injection drug use: An analysis of the National Inpatient Sample. PLoS One. 2021;16(9): e0256757. doi:10.1371/journal.pone.0256757.

277. Squires RW, Kaminsky LA, Porcari JP, et al. Progression of Exercise Training in Early Outpatient Cardiac Rehabilitation. J Cardiopulm Rehabil Prev. 2018;38:139-46. doi:10.1097/HCR.0000000000000337.

278. Pereira SJ. Commentary: Complex valve endocarditis: The importance of early surgical timing with cerebral emboli and a multidisciplinary endocarditis team. J Thorac Cardiovasc Surg. 2024;168(3):843-4. doi:10.1016/j.jtcvs.2023.11.018.

279. Stucki G, Stier-Jarmer M, Grill E, Melvin J. Rationale and principles of early rehabilitation care after an acute injury or illness. Disabil Rehabil 2005;27:353-9. doi:10.1080/09638280400014105.

280. Tam DY, Yanagawa B, Verma S, et al. Early vs Late Surgery for Patients With Endocarditis and Neurological Injury: A Systematic Review and Meta-analysis. Can J Cardiol. 2018;34:1185-99. doi:10.1016/j.cjca.2018.05.010.

281. Hosono M, Sasaki Y, Hirai H, et al. Considerations in timing of surgical intervention for infective endocarditis with cerebrovascular complications. J Heart Valve Dis. 2010;19:321-5.

282. Wasef K, D’etcheverry T, Hayanga JWA, et al. Early Valve Surgery for Endocarditis After Acute Embolic Stroke. Ann Thorac Surg. 2024;118(5):1146-53. doi:10.1016/j.athoracsur.2024.07.017.

283. Marin-Cuartas M, Tang GHL, Kiefer P, et al. Transcatheter heart valve explant with infective endocarditis-associated prosthesis failure and outcomes: the EXPLANT-TAVR international registry. Eur Heart J. 2024;45(28):2519-32. doi:10.1093/eurheartj/ehae292.

284. González I, Sarriá C, López J, et al. Symptomatic Peripheral Mycotic Aneurysms Due to Infective Endocarditis. Medicine (Baltimore). 2014;93:42-52. doi:10.1097/MD.0000000000000014.

285. Uranüs S, Alimoglu O. Splenic Abscess and Infarction — Rare Events for Which Surgery Is Mandatory. Eur Surg. 2003;35:326-6. doi:10.1007/s10353-003-0039-2.

286. Akhyari P, Mehrabi A, Adhiwana A, et al. Is simultaneous splenectomy an additive risk factor in surgical treatment for active endocarditis? Langenbeck’s Arch Surg. 2012;397:1261-6. doi:10.1007/s00423-012-0931-y.

287. Grubitzsch H, Puritz JE, Greve D, et al. Surgery for blood culture-negative infective endocarditis: outcomes and the role of molecular biological imaging as diagnostic approach†. Eur J Cardiothorac Surg. 2024;67(1): ezae453. doi:10.1093/ejcts/ezae453.

288. Nuthalapati U, Bathinapattla MR, Cardoso RP, et al. Mitral valve repair and replacement in infectious endocarditis: a systematic review and meta-analysis of clinical outcome. Egypt Heart J. 2024;76(1):134. doi:10.1186/s43044-024-00564-5.

289. Awad AK, Wilson K, Elnagar MA, et al. To repair or to replace in mitral valve infective endocarditis? an updated meta-analysis. J Cardiothorac Surg. 2024;19(1):247. doi:10.1186/s13019-024-02767-y.

290. Di Bacco L, D’Alonzo M, Di Mauro M, et al. Mitral valve surgery in acute infective endocarditis: long-term outcomes of mitral valve repair versus replacement. J Cardiovasc Med (Hagerstown). 2024;25(1):30-7. doi:10.2459/JCM.0000000000001544.

291. Муратов Р. М., Бакулева Н. П., Зайцев Л. В. и др. Новый биологический кондуит с транслокацией протеза для протезирования корня аорты. Бюллетень НЦССХ им. А. Н. Бакулева РАМН. Сердечно-сосудистые заболевания. 2019;20(S5):167. EDN: ZCSWKT.

292. Федосейкина М. И., Титов Д. А., Бабенко С. И., Муратов Р. М. Хирургическое лечение активного инфекционного эндокардита аортального клапана с абсцессом фиброзного кольца: выбор протеза и клинические результаты. Бюллетень НЦССХ им. А. Н. Бакулева РАМН. Сердечно-сосудистые заболевания. 2024;25(S6_приложение):19. EDN: WXJSTT.

293. Федосейкина М. И., Муратов Р. М. Использование аллографтов в позиции корня аорты и легочной артерии. Грудная и сердечно-сосудистая хирургия. 2020;62(4):282-93. doi:10.24022/0236-2791-2020-62-4-282-293.

294. Sponga S, Di Mauro M, Malvindi PG, et al. Surgery for Bentall endocarditis: short- and midterm outcomes from a multicentre registry. Eur J Cardiothorac Surg. 2020;58(4):839-46. doi:10.1093/ejcts/ezaa136.

295. Galeone A, Trojan D, Gardellini J, et al. Cryopreserved aortic homografts for complex aortic valve or root endocarditis: a 28-year experience. Eur J Cardiothorac Surg. 2022;62(3): ezac193. doi:10.1093/ejcts/ezac193.

296. Tomšič A, Palmen M, de Jong ML, et al. Extensive aortic root endocarditis with extension into the intervalvular fibrous body: an updated report of a mitral valve sparing approach. Eur J Cardiothorac Surg. 2023;63(6): ezad114. doi:10.1093/ejcts/ezad114.

297. Федосейкина М. И., Титов Д. А., Бритиков Д. В. и др. Результаты протезирования корня аорты аортальным аллографтом и легочным аутографтом (операция Росса) при активном инфекционном эндокардите аортального клапана у детей. Сердечно-сосудистые заболевания. Бюллетень НЦССХ им. А. Н. Бакулева РАМН. 2019;20(11-12):986-95. doi:10.24022/1810-0694-2019-20-11-12-986-995.

298. Chauvette V, Bouhout I, Lefebvre L, et al. The Ross procedure is a safe and durable option in adults with infective endocarditis: a multicentre study. Eur J Cardiothorac Surg. 2020;58(3):537-43. doi:10.1093/ejcts/ezaa078.

299. Berretta P, Bifulco O, Luthra S, et al. Surgery for Active Infective Endocarditis on Mitral Valve: Anatomical, Surgical, and Disease Factors as Long-Term Outcome Modifiers. Medicina (Kaunas). 2024;60(6):879. doi:10.3390/medicina60060879.

300. de Kerchove L, Vanoverschelde J-L, Poncelet A, et al. Reconstructive surgery in active mitral valve endocarditis: feasibility, safety and durability. Eur J Cardio-Thoracic Surg. 2007;31:592-9. doi:10.1016/j.ejcts.2007.01.002.

301. Defauw RJ, Tomšič A, van Brakel TJ, et al. A structured approach to native mitral valve infective endocarditis: Is repair better than replacement? Eur J Cardiothorac Surg. 2020;58(3):544-50. doi:10.1093/ejcts/ezaa079.

302. Муратов Р. М., Храмченков А. Г., Сачков А. С. и др. Техника и непосредственные результаты реконструктивных вмешательств на митральном клапане при инфекционном эндокардите. Грудная и сердечно-сосудистая хирургия. 2020;60(3):199-205. doi:10.24022/0236-2791-2020-62-3-199-205.

303. Муратов Р. М., Амирагов Р. И., Бабенко С. И. и др. Отдаленные результаты многокомпонентной реконструкции створок трикуспидального клапана с использованием ауто- и ксеноперикарда при инфекционном эндокардите. Грудная и сердечно-сосудистая хирургия. 2023;65(1):34-42. doi:10.24022/0236-2791-2023-65-1-34-42.

304. Slaughter MS, Badhwar V, Ising M, et al. Optimum surgical treatment for tricuspid valve infective endocarditis: An analysis of the Society of Thoracic Surgeons national database. J Thorac Cardiovasc Surg. 2021;161(4):1227-35. doi:10.1016/j.jtcvs.2019.10.124.

305. Choi JW, Jang MJ, Kim KH, Hwang HY. Repair versus replacement for the surgical correction of tricuspid regurgitation: a meta-analysis. Eur J Cardiothorac Surg. 2018;53(4):748-55. doi:10.1093/ejcts/ezx420.

306. Moore RA, Witten JC, Lowry AM, et al. Isolated mitral valve endocarditis: Patient, disease, and surgical factors that influence outcomes. J Thorac Cardiovasc Surg. 2024;167(1):127-40. doi:10.1016/j.jtcvs.2022.01.058.

307. Храмченков А., Сачков А., Титов Д. и др. Методика поперечной пликации при пролапсе задней створки митрального клапана: техника операции и результаты. Кардиология и сердечно-сосудистая хирургия. 2024;17(4):420-7. doi:10.17116/kardio202417041420.

308. Miura T, Obase K, Ariyoshi T, et al. Impact of Lesion Localization on Durability of Mitral Valve Repair in Infective Endocarditis. Ann Thorac Surg. 2020;109(5):1335-42. doi:10.1016/j.athoracsur.2019.10.010.

309. Pitts L, Moon MC, Luehr M, et al. The Ascyrus Medical Dissection Stent: A One-Fits-All Strategy for the Treatment of Acute Type A Aortic Dissection? J Clin Med. 2024;13(9):2593. doi:10.3390/jcm13092593.

310. Czerny M, Grabenwöger M, Berger T, et al. EACTS/STS Guidelines for Diagnosing and Treating Acute and Chronic Syndromes of the Aortic Organ. Ann Thorac Surg. 2024;118(1):5-115. doi:10.1016/j.athoracsur.2024.01.021.

311. Valencia Nuñez DM, Merino Cejas C, Alados Arboledas P, Muñoz Carvajal I. Heart transplantation in a patient with recurrent early extensive endocarditis. Interact Cardiovasc Thorac Surg. 2013;17(2):423-5. doi:10.1093/icvts/ivt195.

312. Wahba A, Kunst G, De Somer F, et al. 2024 EACTS/EACTAIC/EBCP Guidelines on cardiopulmonary bypass in adult cardiac surgery. Eur J Cardiothorac Surg. 2025;67(2): ezae354. doi:10.1093/ejcts/ezae354.

313. Kahrovic A, Angleitner P, Herkner H, et al. Mechanical versus biological valve prostheses for left-sided infective endocarditis. Eur J Cardiothorac Surg. 2022;62(2): ezac056. doi:10.1093/ejcts/ezac056.

314. Сулейманов Б. Р., Муратов Р. М., Бритиков Д. В. и др. Использование алло- и аутографтов (операция Росса) при активном инфекционном эндокардите с деструкцией корня аорты. Анналы хирургии. 2016;21(3):180-6. EDN: WFISYR.

315. Чернов И. И., Энгиноев С. Т., Кондратьев Д. А. и др. Десятилетние результаты операции Росса у больных с инфекционным эндокардитом: одноцентровое ретроспективное исследование. Кардиология и сердечно-сосудистая хирургия. 2023;16(5):491-7. doi:10.17116/kardio202316051491.

316. Anantha-Narayanan M, Reddy YNV, Sundaram V, et al. Endocarditis risk with bioprosthetic and mechanical valves: systematic review and meta-analysis. Heart. 2020;106(18):1413-9. doi:10.1136/heartjnl-2020-316718.

317. Kahrovic A, Herkner H, Angleitner P, et al. Automated titanium fastener for surgical aortic valve replacement-preventive role for infective endocarditis? Eur J Cardiothorac Surg. 2024;65(6): ezae236. doi:10.1093/ejcts/ezae236.

318. Рыбка М. М., Хинчагов Д. Я., Мумладзе К. В., Никулкина Е. С. Протоколы анестезиологического обеспечения рентгенэндоваскулярных и диагностических процедур, выполняемых у кардиохирургических пациентов различных возрастных групп. Методические рекомендации. М: издательство "НМИЦССХ им. А. Н. Бакулева" Минздрава России, 2018, 74 p. ISBN: 978-5-7982-0385-7.

319. Landoni G, Lomivorotov VV, Nigro Neto C, et al. Volatile Anesthetics versus Total Intravenous Anesthesia for Cardiac Surgery. N Engl J Med. 2019;380. doi:10.1056/nejmoa1816476.

320. Thuny F, Grisoli D, Collart F, et al. Management of infective endocarditis: challenges and perspectives. Lancet. 2012;379:965-75. doi:10.1016/S0140-6736(11)60755-1.

321. Duval X, Alla F, Hoen B, et al. Estimated Risk of Endocarditis in Adults with Predisposing Cardiac Conditions Undergoing Dental Procedures With or Without Antibiotic Prophylaxis. Clin Infect Dis. 2006;42: e102-7. doi:10.1086/504385.

322. Thornhill MH, Jones S, Prendergast B, et al. Quantifying infective endocarditis risk in patients with predisposing cardiac conditions. Eur Heart J. 2018;39:586-95. doi:10.1093/eurheartj/ehx655.

323. Lopez J, Revilla A, Vilacosta I, et al. Definition, clinical profile, microbiological spectrum, and prognostic factors of early-onset prosthetic valve endocarditis. Eur Heart J. 2007;28:760-5. doi:10.1093/eurheartj/ehl486.

324. Horstkotte D. Guidelines on Prevention, Diagnosis and Treatment of Infective Endocarditis Executive Summary The Task Force on Infective Endocarditis of the European Society of Cardiology. Eur Heart J. 2004;25:267-76. doi:10.1016/j.ehj.2003.11.008.

325. Fowler VG, Durack DT, Selton-Suty C, et al. The 2023 Duke-ISCVID Criteria for Infective Endocarditis: Updating the Modified Duke Criteria. Clin Infect Dis. 2023; ciad271. doi:10.1093/cid/ciad271.

326. Husmann L, Huellner MW, Gruenig H, et al. Imaging characteristics and diagnostic accuracy of FDG-PET/CT, contrast enhanced CT and combined imaging in patients with suspected mycotic or inflammatory abdominal aortic aneurysms. PLoS One. 2022;17:e0272772.

327. Anagnostopoulos A, Mayer F, Ledergerber B, et al. VASGRA Cohort Study. Editor’s choice — validation of the management of aortic graft infection collaboration (MAGIC) criteria for the diagnosis of vascular graft/endograft infection: results from the prospective vascular graft cohort study. Eur J Vasc Endovasc Surg. 2021;62:251-7.

328. Tarkin JM, Chen W, Dweck MR, Dilsizian V. Molecular Imaging of Valvular Diseases and Cardiac Device Infection. Circ Cardiovasc Imaging. 2023;16(1):e014652. doi:10.1161/CIRCIMAGING.122.014652.

329. Асланиди И. П., Пурсанова Д. М., Мухортова О. В. и др. Диагностика протезного инфекционного эндокардита по данным позитронно-эмиссионной томографии, совмещенной с компьютерной томографией, с 18F-фтордезоксиглюкозой. Грудная и сердечно-сосудистая хирургия. 2019;61(4):369-73. doi:10.24022/0236-2791-2019-61-4-369-373.

330. Bourque JM, Birgersdotter-Green U, Bravo PE, et al. 18F-FDG PET/CT and Radiolabeled Leukocyte SPECT/CT Imaging for the Evaluation of Cardiovascular Infection in the Multimodality Context: ASNC Imaging Indications (ASNC I2) Series Expert Consensus Recommendations From ASNC, AATS, ACC, AHA, ASE, EANM, HRS, IDSA, SCCT, SNMMI, and STS. JACC Cardiovasc Imaging. 2024;17(6):669-701. doi:10.1016/j.jcmg.2024.01.004. Corrected and republished in: Heart Rhythm. 2024;21(5): e1-e29. doi:10.1016/j.hrthm.2024.01.043.

331. Tornos P, Almirante B, Olona M, et al. Clinical Outcome and Long-Term Prognosis of Late Prosthetic Valve Endocarditis: A 20-Year Experience. Clin Infect Dis. 1997;24:381-6. doi:10.1093/clinids/24.3.381.

332. Truninger K, Jost CHA, Seifert B, et al. Long term follow up of prosthetic valve endocarditis: what characteristics identify patients who were treated successfully with antibiotics alone? Heart. 1999;82:714-20. doi:10.1136/hrt.82.6.714.

333. Hill EE, Herregods M-C, Vanderschueren S, et al. Management of Prosthetic Valve Infective Endocarditis. Am J Cardiol. 2008;101:1174-8. doi:10.1016/j.amjcard.2007.12.015.

334. Culler SD, Cohen DJ, Brown PP, et al. Trends in Aortic Valve Replacement Procedures Between 2009 and 2015: Has Transcatheter Aortic Valve Replacement Made a Difference? Ann Thorac Surg. 2018;105(4):1137-43. doi:10.1016/j.athoracsur.2017.10.057.

335. Barili F, Freemantle N, Pilozzi Casado A, et al. Mortality in trials on transcatheter aortic valve implantation versus surgical aortic valve replacement: a pooled meta-analysis of Kaplan-Meier-derived individual patient data. Eur J Cardiothorac Surg. 2020;58(2):221-9. doi:10.1093/ejcts/ezaa087.

336. Wang TKM, Bin Saeedan M, Chan N, et al. Complementary Diagnostic and Prognostic Contributions of Cardiac Computed Tomography for Infective Endocarditis Surgery. Circ Cardiovasc Imaging. 2020;13(9): e011126. doi:10.1161/CIRCIMAGING.120.011126.

337. Bowdish ME, Habib RH, Kaneko T, et al. Cardiac Surgery After Transcatheter Aortic Valve Replacement: Trends and Outcomes. Ann Thorac Surg. 2024;118(1):155-62. doi:10.1016/j.athoracsur.2024.03.024.

338. Bhushan S, Huang X, Li Y, et al. Paravalvular Leak After Transcatheter Aortic Valve Implantation Its Incidence, Diagnosis, Clinical Implications, Prevention, Management, and Future Perspectives: A Review Article. Curr Probl Cardiol. 2022;47(10):100957. doi:10.1016/j.cpcardiol.2021.100957.

339. Титов Д. А., Соркомов М. Н., Пурсанова Д. М. и др. Репротезирование аортального клапана после ранее выполненного TAVI. Вестник трансплантологии и искусственных органов. 2023;25(3):129-38.

340. Dvir D, Webb JG, Bleiziffer S, et al. Transcatheter aortic valve implantation in failed bioprosthetic surgical valves. JAMA. 2014;312(2):162-70. doi:10.1001/jama.2014.7246.

341. Muensterer A, Puluca N, Ruge H, et al. Surgical explantation of failed transcatheter heart valves: indications and results. Heart Vessels. 2022;37(12):2083-92. doi:10.1007/s00380-022-02119-7.

342. Sohail MR, Uslan DZ, Khan AH, et al. Management and Outcome of Permanent Pacemaker and Implantable Cardioverter-Defibrillator Infections. J Am Coll Cardiol. 2007;49:1851-9. doi:10.1016/j.jacc.2007.01.072.

343. Hussein AA, Baghdy Y, Wazni OM, et al. Microbiology of Cardiac Implantable Electronic Device Infections. JACC Clin Electrophysiol. 2016;2:498-505. doi:10.1016/j.jacep.2016.01.019.

344. Tarakji KG, Chan EJ, Cantillon DJ, et al. Cardiac implantable electronic device infections: Presentation, management, and patient outcomes. Hear Rhythm. 2010;7:1043-7. doi:10.1016/j.hrthm.2010.05.016.

345. Fowler VG Jr, Li J, Corey GR, et al. Role of echocardiography in evaluation of patients with Staphylococcus aureus bacteremia: experience in 103 patients. J Am Coll Cardiol. 1997;30:1072-8. doi:10.1016/S0735-1097(97)00250-7.

346. Victor F, De Place C, Camus C, et al. Pacemaker lead infection: echocardiographic features, management, and outcome. Heart 1999;81:82-7. doi:10.1136/hrt.81.1.82.

347. Vilacosta I, Sarria C, San Roman JA, et al. Usefulness of transesophageal echocardiography for diagnosis of infected transvenous permanent pacemakers. Circulation. 1994;89:2684-7. doi:10.1161/01.CIR.89.6.2684.

348. Bongiorni MG, Di Cori A, Soldati E, et al. Intracardiac Echocardiography in Patients with Pacing and Defibrillating Leads: A Feasibility Study. Echocardiography. 2008;25:632-8. doi:10.1111/j.1540-8175.2008.00656.x.

349. Narducci ML, Pelargonio G, Russo E, et al. Usefulness of Intracardiac Echocardiography for the Diagnosis of Cardiovascular Implantable Electronic Device-Related Endocarditis. J Am Coll Cardiol. 2013;61:1398-405. doi:10.1016/j.jacc.2012.12.041.

350. Dalal A, Asirvatham SJ, Chandrasekaran K, et al. Intracardiac echocardiography in the detection of pacemaker lead endocarditis. J Am Soc Echocardiogr. 2002;15:1027-8. doi:10.1067/mje.2002.121276.

351. Sohail MR, Uslan DZ, Khan AH, et al. Infective Endocarditis Complicating Permanent Pacemaker and Implantable Cardioverter-Defibrillator Infection. Mayo Clin Proc. 2008;83:46-53. doi:10.4065/83.1.46.

352. Rundström H, Kennergren C, Andersson R, et al. Pacemaker Endocarditis During 18 Years in Göteborg. Scand J Infect Dis. 2004;36:674-9. doi:10.1080/00365540410022611.

353. Baddour LM, Bettmann MA, Bolger AF, et al. Nonvalvular Cardiovascular Device-Related Infections. Circulation. 2003;108:2015-31. doi:10.1161/01.CIR.0000093201.57771.47.

354. Huang X-M, Fu H-X, Zhong L, et al. Outcomes of transvenous lead extraction for cardiovascular implantable electronic device infections in patients with prosthetic heart valves. Circ Arrhythm Electrophysiol. 2016;9: e004188. doi:10.1161/CIRCEP.116.004188.

355. Chamis AL, Peterson GE, Cabell CH, et al. Staphylococcus aureus bacteremia in patients with permanent pacemakers or implantable cardioverter-defibrillators. Circulation. 2001;104:1029-33. doi:10.1161/hc3401.095097.

356. Madhavan M, Sohail MR, Friedman PA, et al. Outcomes in patients with cardiovascular implantable electronic devices and bacteremia caused by Gram-positive cocci other than Staphylococcus aureus. Circ Arrhythm Electrophysiol. 2010;3:639-45. doi:10.1161/CIRCEP.110.957514.

357. Sohail MR, Palraj BR, Khalid S, et al. Predicting risk of endovascular device infection in patients with Staphylococcus aureus bacteremia (PREDICT-SAB). Circ Arrhythm Electrophysiol. 2015;8:137-44. doi:10.1161/CIRCEP.114.002199.

358. Uslan DZ, Dowsley TF, Sohail MR, et al. Cardiovascular implantable electronic device infection in patients with Staphylococcus aureus bacteremia. Pacing Clin Electrophysiol. 2010;33:407-13. doi:10.1111/j.1540-8159.2009.02565.x.

359. Бокерия Л. А., Ревишвили А. Ш., Дюжиков А. А. и др. Опыт хирургического удаления эндокардиальных электродов для постоянной электрокардиостимуляции. Анналы Аритмологии. 2006;2:78-81.

360. Pichlmaier M, Knigina L, Kutschka I, et al. Complete removal as a routine treatment for any cardiovascular implantable electronic device-associated infection. J Thorac Cardiovasc Surg. 2011;142:1482-90. doi:10.1016/j.jtcvs.2010.11.059.

361. Sohail MR, Uslan DZ, Khan AH, et al. Risk Factor Analysis of Permanent Pacemaker Infection. Clin Infect Dis. 2007;45:166-73. doi:10.1086/518889.

362. Meier-Ewert HK, Gray M-E, John RM. Endocardial pacemaker or defibrillator leads with infected vegetations: a single-center experience and consequences of transvenous extraction. American Heart Journal. 2003;2(146):339-44.

363. Сергуладзе С. Ю., Артюхина Е. А., Кваша Б. И. и др. Отдаленные результаты имплантации эпикардиальных стероидных электродов после хирургического удаления эндокардиальных электродов у пациента с септическим электродным эндокардитом. Вестник аритмологии. 2016;(83):61-3.

364. Айвазьян С. А., Артюхина Е. А., Гуреев С. В. и др. экстракция электродов сердечных имплантируемых электронных устройств: показания, методики, оснащение, ведение пациентов. Под ред. А. Ш. Ревишвили. М.: Издательский дом ВидарМ, 2021. 144 с., ил. ISBN: 978-5-88429-268-0.

365. Deharo JC, Bongiorni MG, Rozkovec A, et al. "Pathways for training and accreditation for transvenous lead extraction: a European Heart Rhythm Association position paper" Europace. 2012;14:460. doi:10.1093/europace/eus035.

366. Chua JD, Wilkoff BL, Lee I, et al. Diagnosis and management of infections involving implantable electrophysiologic cardiac devices. Ann Intern Med. 2000;133:604-8. doi:10.7326/0003-4819-133-8-200010170-00011.

367. Grammes JA, Schulze CM, Al-Bataineh M, et al. Percutaneous Pacemaker and Implantable Cardioverter-Defibrillator Lead Extraction in 100 Patients With Intracardiac Vegetations Defined by Transesophageal Echocardiogram. J Am Coll Cardiol. 2010;55:886-94. doi:10.1016/j.jacc.2009.11.034.

368. Braun MU, Rauwolf T, Bock M, et al. Percutaneous Lead Implantation Connected to an External Device in Stimulation-Dependent Patients with Systemic Infection — A Prospective and Controlled Study. Pacing Clin Electrophysiol. 2006;29:875-9. doi:10.1111/j.1540-8159.2006.00454.x.

369. Klug D, Balde M, Pavin D, et al. Risk Factors Related to Infections of Implanted Pacemakers and Cardioverter-Defibrillators. Circulation. 2007;116:1349-55. doi:10.1161/CIRCULATIONAHA.106.678664.

370. Kornberger A, Schmid E, Kalender G, et al. Bridge to Recovery or Permanent System Implantation: An Eight-Year Single-Center Experience in Transvenous Semipermanent Pacing. Pacing Clin Electrophysiol. 2013;36:1096-103. doi:10.1111/pace.12175.

371. Kawata H, Pretorius V, Phan H, et al. Utility and safety of temporary pacing using active fixation leads and externalized re-usable permanent pacemakers after lead extraction. Europace. 2013;15:1287-91. doi:10.1093/europace/eut045.

372. Pecha S, Aydin MA, Yildirim Y, et al. Transcutaneous lead implantation connected to an externalized pacemaker in patients with implantable cardiac defibrillator/pacemaker infection and pacemaker dependency. Europace. 2013;15:1205-9. doi:10.1093/europace/eut031.

373. Bertaglia E, Zerbo F, Zardo S, et al. Antibiotic prophylaxis with a single dose of cefazolin during pacemaker implantation: Incidence of long-term infective complications. PACE — Pacing Clin Electrophysiol. 2006;29:29-33. doi:10.1111/j.1540-8159.2006.00294.x.

374. Chiang KH, Chao TF, Lee WS, et al. How long should prophylactic antibiotics be prescribed for permanent pacemaker implantations? one day versus three days. Acta Cardiol Sin. 2013;29:341-6.

375. Wellens F, Pirlet M, Larbuisson R, et al. Prophylaxis in cardiac surgery. A controlled randomized comparison between cefazolin and cefuroxime. Eur J Cardiothorac Surg. 1995;9:325-9. doi:10.1016/S1010-7940(05)80191-5.

376. Ackah JK, Neal L, Marshall NR, et al. Antimicrobial prophylaxis in adult cardiac surgery in the United Kingdom and Republic of Ireland. J Infect Prev. 2021;22:83-90. doi:10.1177/1757177420971850.

377. Hill TE, Kiehl EL, Shrestha NK, et al. Predictors of permanent pacemaker requirement after cardiac surgery for infective endocarditis. Eur Heart J Acute Cardiovasc Care. 2021;10:329-34. doi:10.1177/2048872619848661.

378. Esquer Garrigos Z, George MP, Vijayvargiya P, et al. Clinical presentation, management, and outcomes of cardiovascular implantable electronic device infections due to Gram-negative versus Gram-positive bacteria. Mayo Clin Proc. 2019;94:1268-77. doi:10.1016/j.mayocp.2018.11.029.

379. Uslan DZ, Sohail MR, Friedman PA, et al. Frequency of permanent pacemaker or implantable cardioverter-defibrillator infection in patients with Gram-negative bacteremia. Clin Infect Dis. 2006;43:731-6. doi:10.1086/506942.

380. Uslan DZ, Sohail MR, St Sauver JL, et al. Permanent pacemaker and implantable cardioverter defibrillator infection: a population-based study. Arch Intern Med. 2007;167:669-75. doi:10.1001/archinte.167.7.669.

381. Lakbar I, Delamarre L, Einav S, Leone M. Endocarditis in the intensive care unit: an update. Curr Opin Crit Care. 2022;28(5):503-12. doi:10.1097/MCC.0000000000000973.

382. Joffre J, Dumas G, Aegerter P, et al. Epidemiology of infective endocarditis in French intensive care units over the 1997-2014 period-from CUB-rea network. Crit Care. 2019;23:143. doi:10.1186/s13054-019-2387-8.

383. Leroy O, Georges H, Devos P, et al. Infective endocarditis requiring ICU admission: epidemiology and prognosis. Ann Intensive Care. 2015;5:45. doi:10.1186/s13613-015-0091-7.

384. Samol A, Kaese S, Bloch J, et al. Infective endocarditis on ICU: risk factors, outcome and long-term follow-up. Infection. 2015;43:287-95. doi:10.1007/s15010-014-0715-0.

385. Escola-Verge L, Fernandez-Hidalgo N, Larrosa MN, et al. Secular trends in the epidemiology and clinical characteristics of Enterococcus faecalis infective endocarditis at a referral center (2007-2018). Eur J Clin Microbiol Infect Dis. 2021;40:1137-48. doi:10.1007/s10096-020-04117-x.

386. Nedel W, Boniatti MM, Lisboa T. Endocarditis in critically ill patients: a review. Curr Opin Crit Care. 2023;29:430-37. doi:10.1097/MCC.0000000000001071.

387. Sharma V, Candilio L, Hausenloy DJ. Infective endocarditis: an intensive care perspective. Trends Anaesth Crit Care. 2012;2:36-41. doi:10.1016/j.tacc.2011.11.004.

388. Arntfield R, Lau V, Landry Y, et al. Impact of critical care transesophageal echocardiography in medical-surgical ICU patients: characteristics and results from 274 consecutive examinations. J Intensive Care Med. 2020;35:896-902. doi:10.1177/0885066618797271.

389. Багненко С. Ф., Горобец Е. С., Гусаров В. Г. и др. Клинические рекомендации "Сепсис (у взрослых)". Вестник анестезиологии и реаниматологии. 2025;22(1):80-109. doi:10.24884/2078-5658-2025-22-1-81-109.

390. Киров М. Ю., Кузьков В. В., Проценко Д. Н. и др. Септический шок у взрослых: клинические рекомендации Общероссийской общественной организации "Федерация анестезиологов и реаниматологов". Вестник интенсивной терапии им. А. И. Салтанова. 2023;(4):7-42. doi:10.21320/1818-474X-2023-4-7-42.

391. Lassen H, Nielsen SL, Gill SUA, Johansen IS. The epidemiology of infective endocarditis with focus on non-device related right-sided infective endocarditis: a retrospective register-based study in the region of southern Denmark. Int J Infect Dis. 2020;95:224-30. doi:10.1016/j.ijid.2020.04.011.

392. Lee M-R, Chang S-A, Choi S-H, et al. Clinical Features of Right-Sided Infective Endocarditis Occurring in Non-Drug Users. J Korean Med Sci. 2014;29:776. doi:10.3346/jkms.2014.29.6.776.

393. Stavi V, Brandstaetter E, Sagy I, et al. Comparison of Clinical Characteristics and Prognosis in Patients with Right- and Left-sided Infective Endocarditis. Rambam Maimonides Med J. 2019;10: e0003. doi:10.5041/RMMJ.10338.

394. Asgeirsson H, Thalme A, Weiland O. Low mortality but increasing incidence of Staphylococcus aureus endocarditis in people who inject drugs. Medicine (Baltimore). 2016;95: e5617. doi:10.1097/MD.0000000000005617.

395. Carozza A, De Santo LS, Romano G, et al. Infective endocarditis in intravenous drug abusers: patterns of presentation and long-term outcomes of surgical treatment. J Heart Valve Dis. 2006;15:125-31.

396. Демин А. А., Дробышева В. П., Вельтер О. Ю. Инфекционный эндокардит внутривенных наркоманов. Клиническая медицина. 2000;78:47-51.

397. Venet M, Jalal Z, Ly R, et al. Diagnostic Value of 18F-Fluorodeoxyglucose Positron Emission Tomography Computed Tomography in Prosthetic Pulmonary Valve Infective Endocarditis. JACC Cardiovasc Imaging. 2022;15(2):299-308. doi:10.1016/j.jcmg.2021.07.015.

398. Anton-Vazquez V, Cannata A, Amin-Youssef G, et al. Diagnostic value of 18F-FDG PET/CT in infective endocarditis. Clin Res Cardiol. 2022;111(6):673-9. doi:10.1007/s00392-021-01975-z.

399. Wilson LE, Thomas DL, Astemborski J, et al. Prospective Study of Infective Endocarditis among Injection Drug Users. J Infect Dis. 2002;185:1761-6. doi:10.1086/340827.

400. Martín-Dávila P, Navas E, Fortún J, et al. Analysis of mortality and risk factors associated with native valve endocarditis in drug users: The importance of vegetation size. Am Heart J. 2005;150:1099-106. doi:10.1016/j.ahj.2005.02.009.

401. Hussain ST, Witten J, Shrestha NK, et al. Tricuspid valve endocarditis. Ann Cardiothorac Surg. 2017;6:255-61. doi:10.21037/acs.2017.03.09.

402. Pulvirenti JJ, Kerns E, Benson C, et al. Infective endocarditis in injection drug users: Importance of human immunodeficiency virus serostatus and degree of immunosuppression. Clin Infect Dis. 1996;22:40-5. doi:10.1093/clinids/22.1.40.

403. Sousa C, Botelho C, Rodrigues D, et al. Infective endocarditis in intravenous drug abusers: an update. Eur J Clin Microbiol Infect Dis. 2012;31:2905-10. doi:10.1007/s10096-012-1675-x.

404. Lodise TP, McKinnon PS, Levine DP, Rybak MJ. Impact of empirical-therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillinsusceptible Staphylococcus aureus. Antimicrob Agents Chemother. 2007;51:3731-3. doi:10.1128/AAC.00101-07.

405. Torres-Tortosa M, de Cueto M, Vergara A, et al. Prospective evaluation of a two-week course of intravenous antibiotics in intravenous drug addicts with infective endocarditis. Eur J Clin Microbiol Infect Dis. 1994;13:559-64. doi:10.1007/BF01971306.

406. Yung D, Kottachchi D, Neupane B, et al. Antimicrobials for right-sided endocarditis in intravenous drug users: A systematic review. J Antimicrob Chemother. 2007;60:921-8. doi:10.1093/jac/dkm324.

407. Hecht SR, Berger M. Right-sided endocarditis in intravenous drug users. Prognostic features in 102 episodes. Ann Intern Med. 1992;117:560-6. doi:10.7326/0003-4819-117-7-560.

408. Fortun J, Perez-Molina JA, Anon MT, et al. Right-sided endocarditis caused by Staphylococcus aureus in drug abusers. Antimicrob Agents Chemother. 1995;39:525-8. doi:10.1128/aac.39.2.525.

409. Al-Omari A, Cameron DW, Lee C, Corrales-Medina VF. Oral antibiotic therapy for the treatment of infective endocarditis: a systematic review. BMC Infect Dis. 2014;14:140. doi:10.1186/1471-2334-14-140.

410. Murashita T. Surgical Treatment for Tricuspid Valve Infective Endocarditis. Adv. Concepts Endocarditis, InTech; 2018. doi:10.5772/intechopen.74951.

411. Yanagawa B, Pettersson GB, Habib G, et al. Surgical Management of Infective Endocarditis Complicated by Embolic Stroke: Practical Recommendations for Clinicians. Circulation. 2016;134(17):1280-92. doi:10.1161/CIRCULATIONAHA.116.024156.

412. Navia JL, Elgharably H, Hakim AH, et al. Long-term Outcomes of Surgery for Invasive Valvular Endocarditis Involving the Aortomitral Fibrosa. Ann Thorac Surg. 2019;108(5):1314-23. doi:10.1016/j.athoracsur.2019.04.119.

413. Randhawa VK, Rajani R. Novel Frontiers for Managing Tricuspid Valve Endocarditis: Tales of Percutaneous Extracorporeal Circuitry. JACC Case Rep. 2021;3(11):1350-3. doi:10.1016/j.jaccas.2021.06.026.

414. Brescia AA, Watt TMF, Williams AM, et al. Tricuspid Valve Leaflet Repair and Augmentation for Infective Endocarditis. Oper Tech Thorac Cardiovasc Surg. 2019;24(4):206-18. doi:10.1053/j.optechstcvs.2019.09.002.

415. Baumgartner H, De Backer J, Babu-Narayan SV, et al. 2020 ESC Guidelines for the management of adult congenital heart disease. Eur Heart J. 2021;42(6):563-645. doi:10.1093/eurheartj/ehaa554.

416. Moons P. What do adult patients with congenital heart disease know about their disease, treatment, and prevention of complications? A call for structured patient education. Heart. 2001;86:74-80. doi:10.1136/heart.86.1.74.

417. Niwa K. Infective endocarditis in congenital heart disease: Japanese national collaboration study. Heart. 2005;91:795-800. doi:10.1136/hrt.2004.043323.

418. Kuijpers JM, Koolbergen DR, Groenink M, et al. Incidence, risk factors, and predictors of infective endocarditis in adult congenital heart disease: Focus on the use of prosthetic material. Eur Heart J. 2017;38:2048-56. doi:10.1093/eurheartj/ehw591.

419. Murakami T, Niwa K, Yoshinaga M, Nakazawa M. Factors associated with surgery for active endocarditis in congenital heart disease. Int J Cardiol. 2012;157:59-62. doi:10.1016/j.ijcard.2010.11.016.

420. San Román JA, López J, Vilacosta I, et al. Prognostic Stratification of Patients with Left-Sided Endocarditis Determined at Admission. Am J Med. 2007;120:369.e1-369.e7. doi:10.1016/j.amjmed.2006.05.071.

421. Moore B, Cao J, Kotchetkova I, Celermajer DS. Incidence, predictors and outcomes of infective endocarditis in a contemporary adult congenital heart disease population. Int J Cardiol. 2017;249:161-5. doi:10.1016/j.ijcard.2017.08.035.

422. Foley M. Cardiac disease. In: Dildy G, Belfort M, Saade G, et al. Critical care obstetrics, 5th ed. Oxford: Blackwell; 2004, p.256-283. ISBN: 978-1-4051-5273-0.

423. Montoya ME, Karnath BM, Ahmad M. Endocarditis during Pregnancy. South Med J. 2003;96:1156-7. doi:10.1097/01.SMJ.0000054503.18393.1E.

424. Dajani AS, Bisno AL, Chung KJ, et al. Prevention of bacterial endocarditis. J Endod. 1991;17:169-73. doi:10.1016/S0099-2399(06)82011-X.

425. Roos-Hesselink JW, Ruys TPE, Stein JI, et al. Outcome of pregnancy in patients with structural or ischaemic heart disease: results of a registry of the European Society of Cardiology. Eur Heart J. 2013;34:657-65. doi:10.1093/eurheartj/ehs270.

426. Morissens M, Viart P, Tecco L, et al. Does congenital heart disease severely jeopardise family life and pregnancies? Obstetrical history of women with congenital heart disease in a single tertiary centre. Cardiol Young. 2013:41-6.

427. Mazibuko B, Ramnarain H, Moodley J. An audit of pregnant women with prosthetic heart valves at a tertiary hospital in South Africa. Cardiovasc J Afr. 2012;23:216-21. doi:10.5830/CVJA-2012-022.

428. Aggarwal N, Suri V, Kaur H, et al. Retrospective analysis of outcome of pregnancy in women with congenital heart disease: Single-centre experience from North India. Aust New Zeal J Obstet Gynaecol. 2009;49:376-81. doi:10.1111/j.1479-828X.2009.01029.x.

429. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018;39(34): 3165-241.

430. Raymond M, Countouris M, Marino A, Berlacher KL. Infective endocarditis in pregnancy a contemporary cohort. J Am Coll Cardiol. 2020;75:2145. doi:10.1016/s0735-1097(20)32772-8.

431. Martinez-Selles M, Valerio-Minero M, Farinas MC, et al. Infective endocarditis in patients with solid organ transplantation. A nationwide descriptive study. Eur J Intern Med 2021;87:59-65. doi:10.1016/j.ejim.2021.02.017.

432. Eichenberger EM, Dagher M, Sinclair MR, et al. Infective endocarditis and solid organ transplantation: only worse outcomes during initial transplantation hospitalization. Am Heart J. 2021;240:63-72. doi:10.1016/j.ahj.2021.06.007.

433. Jordan AM, Tatum R, Ahmad D, et al. Infective endocarditis following heart transplantation: a systematic review. Transplant Rev (Orlando). 2021;36:100672. doi:10.1016/j.trre.2021.100672.

434. Timsit JF, Sonneville R, Kalil AC, et al. Diagnostic and therapeutic approach to infectious diseases in solid organ transplant recipients. Intensive Care Med. 2019;45(5):573-91. doi:10.1007/s00134-019-05597-y.

435. Velleca A, Shullo MA, Dhital K, et al. The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2023;42(5): e1-e141. doi:10.1016/j.healun.2022.10.015.

436. Ius F, Moscalenco D, Boethig D, et al. Cardiac valve operations after solid organ transplantation: A single-center experience. J Thorac Cardiovasc Surg. 2021;161(2):595-606. doi:10.1016/j.jtcvs.2019.10.032.

437. Munoz-Moreno MF, Ryan P, Alvaro-Meca A, et al. National temporal trend analysis of infective endocarditis among patients infected with HIV in Spain (1997-2014): a retrospective study. J Clin Med. 2019;8:1167. doi:10.3390/jcm8081167.

438. Sadeghi M, Behdad S, Shahsanaei F. Infective Endocarditis and Its Short and Long-Term Prognosis in Hemodialysis Patients: A Systematic Review and Meta-analysis. Curr Probl Cardiol. 2021;46(3):100680. doi:10.1016/j.cpcardiol.2020.100680.

439. Ludvigsen LU, Dalgaard LS, Wiggers H, et al. Infective endocarditis in patients receiving chronic hemodialysis: A 21-year observational cohort study in Denmark. Am Heart J. 2016;182:36-43. doi:10.1016/j.ahj.2016.08.012.

440. Ding U, Ooi L, Wu HHL, Chinnadurai R. Infective Endocarditis in Patients Receiving Hemodialysis: A Current Review. Kidney Dis (Basel). 2024;10(6):519-30. doi:10.1159/000540513.

441. Bentata Y. Physiopathological approach to infective endocarditis in chronic hemodialysis patients: left heart versus right heart involvement. Renal Failure. 2017;39(1):432-9. doi:10.1080/0886022x.2017.1305410.

442. Volgina G, Kotenko O, Artyukhina L, Frolova N. Infectious endocarditis in hemodialysis patients. Doctor. 2011;13:16-22. (In Russ.) Волгина Г., Котенко О., Артюхина Л., Фролова Н. Инфекционный эндокардит у пациентов на гемодиализе. Врач. 2011;13:16-22.

443. Lok CE, Huber TS, Lee T, et al. KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update. Am J Kidney Dis. 2020;75(4 Suppl 2): S1-S164. doi:10.1053/j.ajkd.2019.12.001. Erratum in: Am J Kidney Dis. 2021;77(4):551. doi:10.1053/j.ajkd.2021.02.002.

444. Loutradis C, Sarafidis PA, Papadopoulos CE, et al. The Ebb and Flow of Echocardiographic Cardiac Function Parameters in Relationship to Hemodialysis Treatment in Patients with ESRD. J Am Soc Nephrol. 2018;29(5):1372-81. doi:10.1681/ASN.2017101102.

445. Ashley C, Dunleavy A. The renal drug handbook: the ultimate prescribing guide for renal practitioners. 5th ed. CRC press; 2018.

446. Bäck C, Hornum M, Møller CJH, Olsen PS. Cardiac surgery in patients with end-stage renal disease on dialysis. Scand Cardiovasc J. 2017;51(6):334-8. doi:10.1080/14017431.2017.1384565.

447. Oullaï A, Cubilier E, Salaouatchi MT, et al. Iatrogenic Infective Endocarditis in Hemodialysis Patients: A Case Report and Review of the Literature. Case Rep Nephrol. 2022;2022:8500299. doi:10.1155/2022/8500299.

448. Doulton T, Sabharwal N, Cairns HS, et al. Infective endocarditis in dialysis patients: new challenges and old. Kidney Int. 2003;64(2):720-7. doi:10.1046/j.1523-1755.2003.00136.x.

449. Llenas-Garcia J, Guerra-Vales JM, Montes-Moreno S, et al. [Nonbacterial thrombotic endocarditis: clinicopathologic study of a necropsy series]. Rev Esp Cardiol. 2007;60:493-500. doi:10.1016/S1885-5857(07)60190-X.

450. Zmaili MA, Alzubi JM, Kocyigit D, et al. A contemporary 20-year Cleveland clinic experience of nonbacterial thrombotic endocarditis: etiology, echocardiographic imaging, management, and outcomes. Am J Med. 2021;134:361-9. doi:10.1016/j.amjmed.2020.06.047.

451. González Quintela A, Candela MJ, Vidal C, et al. Non-bacterial thrombotic endocarditis in cancer patients. Acta Cardiol. 1991;46:1-9.

452. Dutta T, Karas MG, Segal AZ, Kizer JR. Yield of Transesophageal Echocardiography for Nonbacterial Thrombotic Endocarditis and Other Cardiac Sources of Embolism in Cancer Patients With Cerebral Ischemia. Am J Cardiol. 2006;97:894-8. doi:10.1016/j.amjcard.2005.09.140.

453. Lisnevskaia L, Murphy G, Isenberg D. Systemic lupus erythematosus. Lancet. 2014;384;1878-88. doi:10.1016/S0140-6736(14)60128-8.

454. Busca-Arenzana C, Robles-Marhuenda A, Ramos-Ruperto L, Alvarez-Troncoso J. Nonbacterial Thrombotic Endocarditis. In: Infective Endocarditis Edited by Peter Magnusson and Robin Razmi. IntechOpen; 2019, p. 291-4. ISBN: 978-1-78984-012-4. doi:10.5772/intechopen.84398.

455. Bell WR, Starksen NF, Tong S, Porterfield JK. Trousseau’s syndrome. Devastating coagulopathy in the absence of heparin. Am J Med. 1985;79:423-30. doi:10.1016/0002-9343(85)90028-2.

456. Mantovani F, Navazio A, Barbieri A, Boriani G. A first described case of cancer-associated non-bacterial thrombotic endocarditis in the era of direct oral anticoagulants. Thromb Res. 2017;149:45-7. doi:10.1016/j.thromres.2016.11.016.

457. Pengo V, Denas G, Zoppellaro G, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 2018;132:1365-71. doi:10.1182/blood-2018-04-848333.

458. Ferrari A, Botrugno I, Bombelli E, et al. Colonoscopy is mandatory after Streptococcus bovis endocarditis: a lesson still not learned. Case report. World J Surg Oncol. 2008;6:49. doi:10.1186/1477-7819-6-49.

459. WHO Expert Committee on Medical Rehabilitation. First report. World Health Organ Tech Rep Ser. 1958;158:1-52.

460. Hansen TB, Zwisler AD, Berg SK, et al. Cost-utility analysis of cardiac rehabilitation after conventional heart valve surgery versus usual care. Eur J Prev Cardiol. 2017;24(7):698-707. doi:10.1177/2047487317689908.

461. Brown TM, Pack QR, Aberegg E, et al. Core Components of Cardiac Rehabilitation Programs: 2024 Update: A Scientific Statement From the American Heart Association and the American Association of Cardiovascular and Pulmonary Rehabilitation. Circulation. 2024;150(18): e328-e347. doi:10.1161/CIR.0000000000001289.

462. Abreu A, Frederix I, Dendale P, et al. Standardization and quality improvement of secondary prevention through cardiovascular rehabilitation programmes in Europe: The avenue towards EAPC accreditation programme: A position statement of the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology (EAPC). Eur J Prev Cardiol. 2021;28(5):496-509. doi:10.1177/2047487320924912.

463. Rasmussen TB, Zwisler AD, Risom SS, et al. Comprehensive cardiac rehabilitation for patients following infective endocarditis: results of the randomized CopenHeartIE trial. Eur J Cardiovasc Nurs. 2022;21(3):261-70. doi:10.1093/eurjcn/zvab047.

464. Gomes Neto M, Martinez BP, Reis HF, Carvalho VO. Pre- and postoperative inspiratory muscle training in patients undergoing cardiac surgery: systematic review and metaanalysis. Clin Rehabil. 2017;31:454-64. doi:10.1177/0269215516648754.

465. Waite I, Deshpande R, Baghai M, et al. Home-based preoperative rehabilitation (prehab) to improve physical function and reduce hospital length of stay for frail patients undergoing coronary artery bypass graft and valve surgery. J Cardiothorac Surg. 2017;12:91. doi:10.1186/s13019-017-0655-8.

466. Marmelo F, Rocha V, Moreira-Gonçalves D. The impact of prehabilitation on postsurgical complications in patients undergoing non-urgent cardiovascular surgical intervention: Systematic review and meta-analysis. Eur J Prev Cardiol. 2018;25:404-17. doi:10.1177/2047487317752373.

467. Rasmussen T. Health, recovery and rehabilitation after infective endocarditis. Thesis for: PhD in Health and Medical Sciences. 2015. p. 74. doi:10.13140/RG.2.2.20263.75687.

468. Rasmussen TB, Zwisler AD, Sibilitz KL, et al. A randomised clinical trial of comprehensive cardiac rehabilitation versus usual care for patients treated for infective endocarditis-the CopenHeart IE trial protocol. BMJ Open. 2012;2:1929. doi:10.1136/bmjopen-2012-001929.

469. Sanz M, Ceriello A, Buysschaert M, et al. Scientific evidence on the links between periodontal diseases and diabetes: Consensus report and guidelines of the joint workshop on periodontal diseases and diabetes by the International diabetes Federation and the European Federation of Periodontology. Diabetes Res Clin Pract. 2018;137:231-41. doi:10.1016/j.diabres.2017.12.001.

470. Thornhill MH, Gibson TB, Yoon F, et al. Antibiotic Prophylaxis Against Infective Endocarditis Before Invasive Dental Procedures. J Am Coll Cardiol. 2022;80(11):1029-41. doi:10.1016/j.jacc.2022.06.030.

471. Wilson WR, Gewitz M, Lockhart PB, et al. Prevention of Viridans Group Streptococcal Infective Endocarditis: A Scientific Statement From the American Heart Association. Circulation. 2021;143(20): e963-e978. doi:10.1161/CIR.0000000000000969.

472. Corra U, Piepoli MF, Carre F, et al. Secondary prevention through cardiac rehabilitation: physical activity counselling and exercise training: Key components of the position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitat. Eur Heart J. 2010;31:1967-74. doi:10.1093/eurheartj/ehq236.

473. Samuelson G. Global strategy on diet, physical activity and health. Scand J Nutr. 2004;48:57. doi:10.1080/11026480410034349.

474. Hansen D, Abreu A, Ambrosetti M, et al. Exercise intensity assessment and prescription in cardiovascular rehabilitation and beyond: why and how: a position statement from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology. Eur J Prev Cardiol. 2022;29(1):230-45. doi:10.1093/eurjpc/zwab007.

475. Bull FC, Al-Ansari SS, Biddle S, et al. World Health Organization 2020 guidelines on physical activity and sedentary behaviour. Br J Sports Med. 2020;54(24):1451-62. doi:10.1136/bjsports-2020-102955.

476. American College of Sports Medicine. Guidelines for Exercise Testing and Prescription, 11th ed.; Liguori G, Feito Y, Fountaine C, Roy BA, Eds.; Wolters Kluwer Health: Philadelphia, PA, USA, 2021, 906 р.

477. Lockhart PB, Brennan MT, Sasser HC, et al. Bacteremia Associated With Toothbrushing and Dental Extraction. Circulation. 2008;117:3118-25. doi:10.1161/CIRCULATIONAHA.107.758524.

478. Glenny A-M, Oliver R, Roberts GJ, et al. Antibiotics for the prophylaxis of bacterial endocarditis in dentistry. Cochrane Database Syst Rev. 2013;2013: CD003813. doi:10.1002/14651858.CD003813.pub4.

479. van der Meer JTM, Michel MF, Valkenburg HA, et al. Efficacy of antibiotic prophylaxis for prevention of native-valve endocarditis. Lancet. 1992;339:135-9. doi:10.1016/0140-6736(92)90207-J.

480. Lacassin F, Hoen B, Leport C, et al. Procedures associated with infective endocarditis in adults. Eur Heart J. 1995;16:1968-74. doi:10.1093/oxfordjournals.eurheartj.a060855.

481. Isaacs D. Antibiotic prophylaxis for infective endocarditis: A systematic review and metaanalysis. J Paediatr Child Health. 2017;53(9):921-2. doi:10.1111/jpc.13684.

482. Cahill TJ, Harrison JL, Jewell P, et al. Antibiotic prophylaxis for infective endocarditis: A systematic review and meta-Analysis. Heart. 2017;103(12):937-44. doi:10.1136/heartjnl-2015-309102.

483. Brignardello-Petersen R. Antibiotic prophylaxis probably reduces the risk of developing bacteremia in patients at risk of developing infective endocarditis who are undergoing dental extractions. J Am Dent Assoc. 2017;148: e169. doi:10.1016/j.adaj.2017.08.005.

484. Benito N. Health Care-Associated Native Valve Endocarditis: Importance of Nonnosocomial Acquisition. Ann Intern Med. 2009;150:586. doi:10.7326/0003-4819-150-9-200905050-00004.

485. Yu CHY, Minnema BJ, Gold WL. Bacterial infections complicating tongue piercing. Can J Infect Dis Med Microbiol. 2010;21: e70-e74. doi:10.1155/2010/987059.

486. Polyzos KA, Konstantelias AA, Falagas ME. Risk factors for cardiac implantable electronic device infection: a systematic review and meta-analysis. Europace. 2015;17:767-77. doi:10.1093/europace/euv053.

487. Conen A, Stortecky S, Moreillon P, et al. A review of recommendations for infective endocarditis prevention in patients undergoing transcatheter aortic valve implantation. EuroIntervention. 2021;16:1135-40. doi:10.4244/EIJ-D-19-00993.

488. Fernández‐Hidalgo N, Almirante B, Tornos P, et al. Contemporary Epidemiology and Prognosis of Health Care-Associated Infective Endocarditis. Clin Infect Dis. 2008;47:1287-97. doi:10.1086/592576.

489. Selton-Suty C, Célard M, Le Moing V, et al. Preeminence of Staphylococcus aureus in Infective Endocarditis: A 1-Year Population-Based Survey. Clin Infect Dis. 2012;54:1230-9. doi:10.1093/cid/cis199.

490. Lauck SB, Lewis KB, Borregaard B, de Sousa I. "What is the right decision for me?" Integrating patient perspectives through shared decision-making for valvular heart disease therapy. Can J Cardiol. 2021;37:1054-63. doi:10.1016/j.cjca.2021.02.022.

491. Nicolau DP, Freeman CD, Belliveau PP, et al. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother. 1995;39:650-5. doi:10.1128/AAC.39.3.650.

492. Smith JR, Barber KE, Raut A, Rybak MJ. Beta-Lactams enhance daptomycin activity against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium in in vitro pharmacokinetic/pharmacodynamic models. Antimicrob Agents Chemother. 2015;5:2842-8.

493. Dahl A, Rasmussen RV, Bundgaard H, et al. Enterococcus faecalis Infective Endocarditis. Circulation. 2013;127:1810-7. doi:10.1161/CIRCULATIONAHA.112.001170.

494. Olaison L, Schadewitz K. Enterococcal Endocarditis in Sweden, 1995-1999: Can Shorter Therapy with Aminoglycosides Be Used? Clin Infect Dis. 2002;34:159-66. doi:10.1086/338233.

495. Krishnan A, Rajakumar I, Salmon J. Vancomycin-Resistant Enterococcus Faecium Prosthetic Valve Endocarditis Treated with Daptomycin and Ampicillin Combination. J Assoc Med Microbiol Infect Dis Can. 2025;10(1):90-6. doi:10.3138/jammi-2023-0038.

496. Lee SJ, Kim JH, Lee HJ, et al. Comparing Treatment Outcomes of Ampicillin-Sulbactam, Other β-Lactams, and Vancomycin in Blood Culture-Negative Infective Endocarditis. Antibiotics (Basel). 2021;10(12):1476. doi:10.3390/antibiotics10121476.

497. Ramos MC, Ing M, Kim E, et al. Ampicillin-sulbactam is effective in prevention and therapy of experimental endocarditis caused by beta-lactamase-producing coagulase-negative staphylococci. Antimicrob Agents Chemother. 1996;40(1):97-101. doi:10.1128/AAC.40.1.97.

498. Hubert S, Thuny F, Resseguier N, et al. Prediction of Symptomatic Embolism in Infective Endocarditis. J Am Coll Cardiol. 2013;62:1384-92. doi:10.1016/j.jacc.2013.07.029.

499. Mezzani A, Hamm LF, Jones AM, et al. Aerobic exercise intensity assessment and prescription in cardiac rehabilitation: a joint position statement of the European Association for Cardiovascular Prevention and Rehabilitation, the American Association of Cardiovascular and Pulmonary Rehabilitation and the Canadian Association of Cardiac Rehabilitation. Eur J Prev Cardiol. 2013;20:442-67. doi:10.1177/2047487312460484.

500. Global recommendations on physical activity for health. Geneva: WHO. 2010. p. 58. ISBN: 9789241599979.

501. Fletcher GF, Balady GJ, Amsterdam EA, et al. Exercise standards for testing and training: a statement for healthcare professionals from the American Heart Association. Circulation. 2001;104:1694-740. doi:10.1161/HC3901.095960.

502. Hansen D, Dendale P, Coninx K, et al. The European Association of Preventive Cardiology Exercise Prescription in Everyday Practice and Rehabilitative Training (EXPERT) tool: A digital training and decision support system for optimized exercise prescription in cardiovascular disease. Concept, definitions and construction methodology. Eur J Prev Cardiol. 2017;24:1017-31. doi:10.1177/2047487317702042.

503. Karvonen MJ, Kentala E, Mustala O. The effects of training on heart rate; a longitudinal study. Ann Med Exp Biol Fenn. 1957;35:307-15.

504. Ainsworth BE, Haskell WL, Herrmann SD, et al. 2011 Compendium of Physical Activities: a second update of codes and MET values. Undefined. 2011;43:1575-81. doi:10.1249/MSS.0B013E31821ECE12.

505. Kaminsky LA, Brubaker PH, Guazzi M, et al. Assessing Physical Activity as a Core Component in Cardiac Rehabilitation: A position statement of the american association of cardiovascular and pulmonary rehabilitation. J Cardiopulm Rehabil Prev. 2016;36:217-26. doi:10.1097/HCR.0000000000000191.

Документы

Источник

Информация

Автор

Название журнала

Российский кардиологический журнал

Ключевые слова

Статья